Antibody binding to HLA-a02 / NDC80 complex and use thereof

By developing a bispecific antibody that combines the HLA-A02/NDC80 complex and CD3 molecules, the challenge of tumor cell targeting was solved, achieving effective activation and killing of HLA-A02/NDC80 positive tumors and demonstrating significant anti-tumor effects.

WO2026233226A1PCT designated stage Publication Date: 2026-11-12BEIJING WISDOMAB BIOTECHNOLOGY CO LTD +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/094166
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-08
Filing Date
2026-04-30
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing technologies have difficulty effectively targeting the NDC80 protein in tumor cells, resulting in poor efficacy of tumor immunotherapy.

Method used

We developed bispecific antibodies that combine the HLA-A02/NDC80 complex and the activating T-cell antigen CD3 molecule, and prepared TCR mimic antibodies through genetic engineering to achieve specific recognition and activation of tumor cells.

Benefits of technology

It effectively activated and killed HLA-A02/NDC80 positive tumor cells, demonstrating significant anti-tumor effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2026094166-FTAPPB-I100001
    Figure PCTCN2026094166-FTAPPB-I100001
  • Figure PCTCN2026094166-FTAPPB-I100002
    Figure PCTCN2026094166-FTAPPB-I100002
  • Figure PCTCN2026094166-FTAPPB-I100003
    Figure PCTCN2026094166-FTAPPB-I100003
Patent Text Reader

Abstract

Provided are a bispecific antibody containing a first antigen-binding fragment binding to an HLA-A02 / NDC80 complex and a second antigen-binding fragment binding to a T-cell activation antigen, a single-domain antibody binding to an HLA-A02 / NDC80 complex, a pharmaceutical composition containing the bispecific antibody or the single-domain antibody, and the use thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Antibodies that bind to the HLA-A02 / NDC80 complex and their applications

[0001] Related applications

[0002] This application claims priority and benefit to Chinese Patent Application No. CN202510591766.X, filed on May 8, 2025, entitled “Antibody Conjugating HLA-A02 / NDC80 Complex and Its Use Thereof,” which is incorporated herein by reference in its entirety for all purposes. Technical Field

[0003] This application generally relates to the fields of genetic engineering and antibody pharmaceuticals; specifically, it relates to single-domain antibodies that bind to the HLA-A02 / NDC80 complex, bispecific antibodies that bind to the HLA-A02 / NDC80 complex and activated T-cell antigens, and their uses. Background Technology

[0004] NDC80, also known as Hec1 (highly expressed in cancer), is a kinetochore protein that promotes the formation of kinetochore-microtubule structures through electrostatic interactions between its N-terminal tail region and microtubules. The NDC80 protein complex, also known as the Hec1 complex, is located in the kinetochore. One molecule of the Hec1 protein complex comprises four protein molecules: Ndc80p (Hec1p), Nuf2p, Spc24p, and Spc25p. These proteins work in conjunction with other kinetochore proteins to regulate the normal segregation of chromosomes during mitosis. [1,2] The expression level of NDC80 protein changes dynamically with the cell cycle, and it is highly expressed in rapidly dividing cells such as tumor cells. [3] .

[0005] NDC80 protein is expressed in actively dividing cells, but not in terminally differentiated cells. (Chen et al.) [4]Sampling was performed on different organs of adult mice, followed by lysis and immunoblotting. The results showed that NDC80 protein was expressed in tissues with high mitotic rates (such as the testes, ovaries, uterus, spleen, and thymus), but not in terminally differentiated tissues (such as the brain, heart, lungs, liver, and kidneys). NDC80 protein is highly expressed in tumor cells, hence its name Hec1: a highly expressed cancer protein. The expression level of Hec1 protein was higher in most tumor cell lines (such as cervical cancer cell lines HeLa, C4-I, SiHa, Caski, MS751, HT-3; ovarian cancer cell lines Hey, SKOV3; colon cancer cell lines HCT8, HCT116, CACO2, SW480; pancreatic cancer cell line panc-1, etc.) than in normal tissues and non-transformed cell lines. These observations highlight the crucial role of NDC80 in tumorigenesis and suggest it as a potential mitotic target for tumor intervention. [5,6] .

[0006] T cell receptors (TCRs) are characteristic markers on the surface of all T cells. They bind nonvalently to CD3, forming the TCR-CD3 complex. The function of the TCR is to recognize antigens, specifically peptide-MHC complexes (p-MHC). Intracellular proteins are degraded by the proteasome, and the resulting peptides are transported to the endoplasmic reticulum to assemble with MHC-I to form complexes. These complexes are then transported via the Golgi apparatus and finally presented on the cell surface, forming antigens that can be recognized by the TCR. Some of these proteins are specifically expressed in tumors or diseases and can serve as specific target antigens in treatment. Researchers have discovered that preparing TCR mimic antibodies (TCRm) can effectively mimic the TCR, recognize tumor-specific antigen MHC complexes, and exert biological activity with the help of T cells. [7,8,9] Therefore, the development of bispecific antibody drugs based on TCRm×anti-CD3 has become another important area of ​​drug development.

[0007] The complex of HLA-A02 and ALNEQIARL (SEQ ID NO:1) derived from NDC80 (SEQ ID NO:2) can serve as a widely existing target for tumor immunotherapy, exhibiting high abundance in hematologic malignancies and solid tumors.

[0010] .

[0008] Based on clinical needs, exploring and developing bispecific antibodies targeting NDC80 has important biological and clinical significance. Summary of the Invention

[0009] In one aspect, this application provides a bispecific antibody comprising a first antigen-binding fragment that binds to the HLA-A02 / NDC80 complex and a second antigen-binding fragment that binds to activated T-cell antigens.

[0010] In some embodiments of the first aspect, the binding epitope of the first antigen-binding fragment to the HLA-A02 / NDC80 complex includes one or more residues from positions 274-282 (SEQ ID NO:1) of the NDC80 amino acid sequence as shown in SEQ ID NO:2. In some specific embodiments, the binding epitope of the first antigen-binding fragment to the HLA-A02 / NDC80 complex includes at least one of residues from positions 275, 276, 278, 279, and 280 of the NDC80 amino acid sequence as shown in SEQ ID NO:2.

[0011] In some embodiments of the first aspect, the first antigen-binding fragment comprises HCDR1 as shown in SEQ ID NO:18, HCDR2 as shown in SEQ ID NO:19, and HCDR3 as shown in SEQ ID NO:20, wherein the amino acid sequence of HCDR is defined according to the Kabat scheme.

[0012] In some embodiments of the first aspect, the first antigen-binding fragment is in the form of a single-domain antibody. For example, the first antigen-binding fragment comprises a monovalent or multivalent single-domain antibody that binds to the HLA-A02 / NDC80 complex.

[0013] In some embodiments of the first aspect, the first antigen-binding fragment comprises a heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:17 or 27.

[0014] In some embodiments of the first aspect, the activating T-cell antigen is a CD3 molecule.

[0015] In some embodiments of the first aspect, the second antigen-binding fragment comprises HCDR1 as shown in SEQ ID NO:30, HCDR2 as shown in SEQ ID NO:31, HCDR3 as shown in SEQ ID NO:32, LCDR1 as shown in SEQ ID NO:34, LCDR2 as shown in SEQ ID NO:35, and LCDR3 as shown in SEQ ID NO:36, wherein the amino acid sequences of HCDR and LCDR are defined according to the Kabat scheme.

[0016] In some embodiments of the first aspect, the second antigen-binding fragment is in the form of a single-chain antibody (scFv) or a Fab fragment. In some specific embodiments, the second antigen-binding fragment is in the form of scFv.

[0017] In some embodiments of the first aspect, the second antigen-binding fragment comprises a heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:29 and a light chain variable region with an amino acid sequence as shown in SEQ ID NO:33.

[0018] The first antigen-binding fragment may include a heavy chain variable region as shown in SEQ ID NO:17, and the second antigen-binding fragment may include a heavy chain variable region as shown in SEQ ID NO:29 and a light chain variable region as shown in SEQ ID NO:33. Alternatively, the first antigen-binding fragment may include a heavy chain variable region as shown in SEQ ID NO:27, and the second antigen-binding fragment may include a heavy chain variable region as shown in SEQ ID NO:29 and a light chain variable region as shown in SEQ ID NO:33.

[0019] In some embodiments of the first aspect, the bispecific antibody comprises a first arm that binds to the HLA-A02 / NDC80 complex and a second arm that binds to an activated T-cell antigen, wherein

[0020] The first arm comprises an amino acid sequence as shown in SEQ ID NO:39 or 40; and

[0021] The second arm contains an amino acid sequence as shown in SEQ ID NO:41.

[0022] Secondly, this application provides a single-domain antibody that binds to the HLA-A02 / NDC80 complex, which contains

[0023] The amino acid sequence of HCDR1 is shown in SEQ ID NO:18.

[0024] The amino acid sequence is HCDR2 as shown in SEQ ID NO:19, and

[0025] The amino acid sequence is HCDR3 as shown in SEQ ID NO:20;

[0026] The amino acid sequence of HCDR is defined according to the Kabat scheme.

[0027] In some embodiments of the second aspect, the single-domain antibody is a monovalent or multivalent single-domain antibody form that binds to the HLA-A02 / NDC80 complex.

[0028] In some embodiments of the second aspect, the single-domain antibody comprises a heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:17 or 27.

[0029] Thirdly, this application provides a nucleic acid molecule that encodes the bispecific antibody described in the first aspect or the single-domain antibody described in the second aspect.

[0030] Fourthly, this application provides a pharmaceutical composition comprising the bispecific antibody described in the first aspect or the single-domain antibody described in the second aspect, as well as a pharmaceutically acceptable excipient, diluent, or carrier.

[0031] Fifthly, this application provides the use of the bispecific antibody described in the first aspect, the single-domain antibody described in the second aspect, or the pharmaceutical composition described in the fourth aspect in the preparation of a medicament for the prevention or treatment of HLA-A02 / NDC80 positive tumors.

[0032] In a sixth aspect, this application provides a method for preventing or treating HLA-A02 / NDC80 positive tumors, the method comprising administering to a subject in need an effective amount of the bispecific antibody of the first aspect, the single-domain antibody of the second aspect, or the pharmaceutical composition of the fourth aspect.

[0033] In some embodiments of the fifth and / or sixth aspects, the HLA-A02 / NDC80 positive tumors are selected from: acute myeloid leukemia, pancreatic cancer, cervical cancer, ovarian cancer, lung cancer, liver cancer, breast cancer, and colon cancer. Attached Figure Description

[0034] Figure 1 shows the results of ELISA detection of the binding of TCRm antibody N2G1 against the HLA-A02 / NDC80 complex to recombinant protein MIP-N1-A0201.

[0035] Figure 2 shows the N2G1-specific binding antigenic peptide NDC80 analyzed by flow cytometry. 274-282 Results of (ALNEQIARL) pulsed T2 cells.

[0036] Figure 3 shows the results of flow cytometry analysis of T2 cells that specifically bind to the alanine variant pulse of the antigenic peptide NDC80274-282 (ALNEQIARL) using N2G1.

[0037] Figure 4 shows the results of ELISA detection of the simultaneous recognition of MIP-N1-A0201 and CD3 by the TCRm / anti-CD3 bispecific antibodies N2G1 / anti-CD3 and N2G1-h9 / anti-CD3.

[0038] Figure 5 shows the results of T2 cell-specific activation of Jurkat-Dual cells mediated by bispecific antibodies N2G1 / anti-CD3 and N2G1-h9 / anti-CD3-mediated antigen peptide pulses.

[0039] Figure 6 shows the bispecific antibodies N2G1 / anti-CD3 and N2G1-h9 / anti-CD3 mediating PBMC-specific killing of HLA-A02. + / NDC80 + Results of OCI-AML2 cells.

[0040] Figure 7 shows the N2G1-h9 / anti-CD3 mediated by NDC80. 274-282 Results of T2 cell activation of Jurkat-Dual cells by alanine scanning variant pulses.

[0041] Figure 8A shows N2G1-h9 / anti-CD3 mediated loading of NDC80. 274-282 The result of T2 cell activation of Jurkat-Dual by sequence-similar peptides.

[0042] Figure 8B shows the N2G1-h9 / anti-CD3 mediated loading of NDC80 274-282 The result of T2 cell activation of Jurkat-Dual by key amino acid-like peptides.

[0043] Figure 9A shows the results of activation of Jurkat-Dual cells by 293T cells transfected with N2G1-h9 / anti-CD3 bispecific antibody-mediated similar peptide gene.

[0044] Figure 9B shows the results of N2G1-h9 / anti-CD3 bispecific antibody-mediated killing of 293T cells transfected with similar peptide genes by PBMCs.

[0045] Figure 10 shows the results of the N2G1-h9 / anti-CD3 bispecific antibody inhibiting the growth of OCI-AML2 tumors in vivo.

[0046] Figure 11 shows the results of the N2G1-h9 / anti-CD3 bispecific antibody inhibiting the growth of HepG2 tumors in vivo.

[0047] Sequence Description

[0048] SEQ ID NO:1 shows the amino acid sequence of the antigenic peptide ALNEQIARL at positions 274-282 of the human (homo sapiens) NDC80 protein.

[0049] SEQ ID NO:2 shows the amino acid sequence of the human (homo sapiens) NDC80 protein.

[0050] SEQ ID NO:3 shows the amino acid sequence of the extracellular region (hCD3E) of human (homo sapiens) CD3E.

[0051] SEQ ID NO:4 shows the amino acid sequence of the extracellular region (hCD3D) of human (homo sapiens) CD3D.

[0052] SEQ ID NO:5 shows the amino acid sequence of a complex (MIP-N1-A0201) of the NDC80 antigen peptide ALNEQIARL and the disulfide-trapping single-chain trimer of HLA-A0201.

[0053] SEQ ID NO:6 shows the amino acid sequence of the His tag.

[0054] SEQ ID NO:7 shows the amino acid sequence of the Fc segment (mFc) of the mouse (mus musculus) IgG2a antibody.

[0055] SEQ ID NO:8 shows the amino acid sequence of the constant region of the heavy chain of the human (homo sapiens) IgG1 subtype.

[0056] SEQ ID NO:9 shows the amino acid sequence of the human (homo sapiens) IgG1 subtype antibody heavy chain constant region mutant IgG1H.

[0057] SEQ ID NO:10 shows the amino acid sequence of the human (homo sapiens) IgG1 subtype antibody heavy chain constant region mutant IgG1K.

[0058] SEQ ID NO:11 shows the amino acid sequence of the human (homo sapiens) IgG1 subtype antibody heavy chain constant region mutant IgG1m3-H.

[0059] SEQ ID NO:12 shows the amino acid sequence of the human (homo sapiens) IgG1 subtype antibody heavy chain constant region mutant IgG1m3-K.

[0060] SEQ ID NO:13 shows the amino acid sequence of the human (homo sapiens) IgG1 subtype antibody heavy chain constant region mutant IgG1m3-H1n1.

[0061] SEQ ID NO:14 shows the amino acid sequence of the human (homo sapiens) IgG1 subtype antibody heavy chain constant region mutant IgG1m3-Kn1.

[0062] SEQ ID NO:15 shows the amino acid sequence of the constant region of the light chain of the human (homo sapiens) λ subtype.

[0063] SEQ ID NO:16 shows the amino acid sequence of the constant region of the light chain of the human (homo sapiens) κ subtype.

[0064] SEQ ID NO:17 shows the amino acid sequence of the heavy chain variable region of the llama (Llama) single-domain antibody N2G1.

[0065] SEQ ID NO:18-20 show the amino acid sequences of HCDR1, HCDR2 and HCDR3 of the heavy chain variable region of llama (Llama) single-domain antibodies N2G1 and N2G1-h9, respectively.

[0066] SEQ ID NO:21 shows the amino acid sequence of the variable region of the heavy chain of the negative control antibody DP47.

[0067] SEQ ID NO:22 shows the amino acid sequence of the variable region of the light chain of the negative control antibody DP47.

[0068] SEQ ID NO:23-26 show the FR1, FR2, FR3 and FR4 amino acid sequences of the humanized molecule N2G1-h9 of the llama (Llama) single-domain antibody N2G1.

[0069] SEQ ID NO:27 shows the amino acid sequence of the heavy chain variable region of the humanized single-domain antibody N2G1-h9.

[0070] SEQ ID NO:28 shows the amino acid sequence of the single-chain antibody (anti-CD3-ScFv) against human (homo sapiens) CD3.

[0071] SEQ ID NO:29 shows the amino acid sequence of the heavy chain variable region in the single-chain antibody anti-CD3-ScFv.

[0072] SEQ ID NO:30-32 shows the amino acid sequences of HCDR1, HCDR2 and HCDR3 in the heavy chain variable region of the single-chain antibody anti-CD3-ScFv.

[0073] SEQ ID NO:33 shows the amino acid sequence of the light chain variable region in the single-chain antibody anti-CD3-ScFv.

[0074] SEQ ID NO:34-36 shows the amino acid sequences of LCDR1, LCDR2 and LCDR3 in the light chain variable region of the single-chain antibody anti-CD3-ScFv.

[0075] SEQ ID NO:37 shows the amino acid sequence of the Fc fragment IgG1m3-FcH1n1-3C fused with a Hole mutation encoding the Hole mutation.

[0076] SEQ ID NO:38 shows the amino acid sequence of an Fc fragment IgG1m3-FcKn1-3C fused with a Knob mutation.

[0077] SEQ ID NO:39 shows the amino acid sequence of N2G1-G1m3-FcH1n1-3C in the bispecific antibody N2G1 / anti-CD3.

[0078] SEQ ID NO:40 shows the amino acid sequence of N2G1-h9-G1m3-FcH1n1-3C in the bispecific antibody N2G1-h9 / anti-CD3.

[0079] SEQ ID NO:41 shows the amino acid sequence of arm anti-CD3-ScFv-G1m3-FcKn1-3C in the bispecific antibodies N2G1 / anti-CD3 and N2G1-h9 / anti-CD3.

[0080] SEQ ID NO:42-50 show the amino acid sequences of the alanine scanning mutant peptide of the NDC80 antigenic peptide ALNEQIARL at positions 274-282.

[0081] SEQ ID NO:51 shows the amino acid sequence of the irrelevant antigenic peptide used in the examples.

[0082] SEQ ID NO:52-58 show the amino acid sequences of similar peptides NDC80-S1 to NDC80-S7 of the antigenic peptide ALNEQIARL at positions 274-282 of NDC80.

[0083] SEQ ID NO:59-81 show the amino acid sequences of similar peptides NDC80-N2G1-S1 to NDC80-N2G1-S23 of the antigenic peptide ALNEQIARL at positions 274-282 of NDC80.

[0084] SEQ ID NO:82-85 show the amino acid sequences of human (homo sapiens) STXB1 protein, NES protein, MSH3 and DCTN1, respectively.

[0085] SEQ ID NO:86 shows the primer sequence designed for the amino acid CH2 of the heavy chain constant region of the antibody derived from llamas (Llama).

[0086] SEQ ID NO:87 shows the amino acid sequence of DP47VH-IgG1m3-H1n1 in the isotype control molecule DP47 / anti-CD3.

[0087] SEQ ID NO:88 shows the amino acid sequence of DP47VK-Cκ in the isotype control molecule DP47 / anti-CD3.

[0088] SEQ ID NO:89 shows the amino acid sequence of a complex of the NDC80 antigen peptide ALNEQIARL and the disulfide-trapping single-chain trimer of HLA-A0203 (MIP-N1-A0203).

[0089] SEQ ID NO:90 shows the amino acid sequence of a complex of the NDC80 antigenic peptide ALNEQIARL and the disulfide-trapping single-chain trimer of HLA-A0206 (MIP-N1-A0206).

[0090] SEQ ID NO:91 shows the amino acid sequence of a complex of the NDC80 antigen peptide ALNEQIARL and the disulfide-trapping single-chain trimer of HLA-A0207 (MIP-N1-A0207). Detailed Implementation

[0091] Molecules targeting the NDC80 / MHC complex (e.g., the NDC80 / HLA-A02 complex) can serve as effective therapeutic agents on their own or as carriers capable of delivering potent anticancer agents such as drugs, toxins, and radioactive elements.

[0092] Bispecific antibodies (e.g., TCRm bispecific antibodies) are prepared by genetic engineering to bind a first antigen-binding fragment that binds to the HLA-A02 / NDC80 complex and a second antigen-binding fragment that binds to an activating T-cell antigen (e.g., CD3 molecule). The first antigen-binding fragment of the HLA-A02 / NDC80 complex binds to the NDC80 epitope peptide ALNEQIARL (SEQ ID NO:1) and the HLA-A02 complex presented on the surface of target cells (e.g., tumor cells), while the second antigen-binding fragment binds to an activating T-cell antigen (e.g., CD3 molecule). This establishes an interaction between the target cells and T cells, activating the T cells and lysing the target cells (e.g., tumor cells), thereby achieving the purpose of treating diseases (e.g., tumors). In various aspects of this application, bispecific antibodies comprising a first antigen-binding fragment binding to the HLA-A02 / NDC80 complex and a second antigen-binding fragment binding to an activating T-cell antigen (e.g., CD3 molecule), single-domain antibodies binding to the HLA-A02 / NDC80 complex, nucleic acid molecules encoding the bispecific antibody or the single-domain antibody, vectors containing the nucleic acid molecules, host cells containing the nucleic acid molecules or the vector, methods for preparing the bispecific antibody or the single-domain antibody, and medical and biological applications of the bispecific antibody or the single-domain antibody are provided. Based on the sequences of the bispecific antibody or single-domain antibody provided in this application, bispecific antibodies or single-domain antibodies binding to the HLA-A02 / NDC80 complex can be constructed as drugs for clinical use in the prevention or treatment of diseases (e.g., tumors).

[0093] Unless otherwise specified, this application employs conventional molecular biology, microbiology, cell biology, biochemistry, and immunology techniques in the art.

[0094] Unless otherwise specified, the terms used in this application have the meanings commonly understood by those skilled in the art.

[0095] definition

[0096] As used herein, the term "HLA-A02 / NDC80 complex" refers to a complex of the HLA-A02 molecule and NDC80. In some specific embodiments of this application, "HLA-A02 / NDC80 complex" refers to the HLA-A02 molecule and positions 274-282 (NDC80) of NDC80 shown in SEQ ID NO:2. 274-282 , ALNEQIARL, HLA-A02 / NDC80 of SEQ ID NO:1) 274-282 Complex.

[0097] As used herein, the term "activating T-cell antigen" refers to antigenic determinants expressed on the surface of T lymphocytes, particularly cytotoxic T lymphocytes, which can induce T-cell activation upon interaction with antigen-binding molecules. Specifically, the interaction between antigen-binding molecules and activating T-cell antigens can induce T-cell activation by triggering a signaling cascade of the T-cell receptor complex. In a particular aspect, the activating T-cell antigen is the CD3 molecule.

[0098] In a broad sense, the term "antibody" refers to an immunoglobulin molecule capable of specifically binding to a target via at least one antigen recognition site located in the variable region of an immunoglobulin molecule. Therefore, it encompasses complete antibodies / full-length antibodies, single-chain antibodies, or any antigen-binding fragment (also called an "antigen-binding moiety") of an antibody, such as Fab, Fab', F(ab')2, Fv, their variants, fusion proteins containing antibody moieties, humanized antibodies, chimeric antibodies, biantibodies, linear antibodies, single-chain antibodies, multispecific antibodies (e.g., bispecific antibodies), and any other modified configuration of an immunoglobulin molecule containing an antigen recognition site of desired specificity, including glycosylated variants of antibodies, amino acid sequence variants of antibodies, and covalently modified antibodies. When "antibody" and "antigen-binding fragment / antigen-binding moiety" appear in the same context, "antibody" can be understood as the complete form relative to the "antigen-binding fragment / antigen-binding moiety," both corresponding to the broad concept of antibody.

[0099] Typically, a full-length or complete antibody consists of two heavy chains and two light chains. Each heavy chain contains a heavy chain variable region (VH) and first, second, and third constant regions (CH1, CH2, and CH3). Each light chain contains a light chain variable region (VL) and a constant region (CL). Full-length antibodies can be any type of antibody, such as IgD, IgE, IgG, IgA, or IgM (or subclasses mentioned above), but the antibody does not need to belong to any specific class. Immunoglobulins can be assigned to different classes based on the antibody amino acid sequence of the constant region of the heavy chain. Generally, there are five main classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these classes can be further subdivided into subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant regions corresponding to different immunoglobulin classes are called α, δ, ε, γ, and μ, respectively. The subunit structures and three-dimensional structures of different classes of immunoglobulins are well known.

[0100] As used herein, the terms "antigen-binding fragment" or "antigen-binding region" are used interchangeably and refer to a portion or region of the complete antibody molecule responsible for binding the antigen. The antigen-binding domain may contain a heavy chain variable region (VH), a light chain variable region (VL), or both. Each of the VH and VL typically contains three complementarity-determining regions, CDR1, CDR2, and CDR3.

[0101] It is well known to those skilled in the art that complementarity-determining regions (CDRs, typically CDR1, CDR2, and CDR3) are the regions in the variable region that have the greatest impact on antibody affinity and specificity. There are two common definitions for the CDR sequence of VH or VL: the Kabat definition and the Chothia definition. (See, for example, Kabat, “Sequences of Proteins of Immunological Interest”, National Institutes of Health, Bethesda, MD. (1991))

[0011] ;A1-Lazikani et al., J. Mol. Biol. 273:927-948 (1997)

[0012] ; and Martin et al., Proc. Natl. Acad. Sci. USA 86:9268-9272 (1989))

[0013] For a given antibody's variable region sequence, the CDR region sequence in the VH and VL sequences can be determined according to the Kabat definition or the Chothia definition. In the embodiments of this application, the Kabat definition of the CDR sequence is used.

[0102] For a given antibody's variable region sequence, the CDR region sequence can be analyzed in various ways, such as using the online software Abysis (http: / / www.abysis.org / ).

[0103] Examples of antigen-binding fragments for general antibodies include, but are not limited to: (1) Fab fragments, which may be monovalent fragments having VL-CL chains and VH-CH1 chains; (2) F(ab')2 fragments, which may be divalent fragments having two Fab' fragments connected by disulfide bridges (i.e., Fab' dimers) in the hinge region; (3) Fv fragments having a single arm of antibody with VL and VH domains; (4) single-chain Fv(scFv), which may be a single polypeptide chain consisting of VH and VL domains connected by peptide linkers; (5) (scFv)2, which may contain two VH domains and two VL domains connected by peptide linkers, the two VL domains being combined with the two VH domains via disulfide bridges; and (6) single-domain antibody forms.

[0104] As used herein, the term "bispecific antibody" refers to an antibody that simultaneously binds to two antigenic epitopes. These two epitopes can be on different antigens or on the same antigen. Bispecific antibodies can have various structural configurations. For example, a bispecific antibody can consist of two Fc fragments and two binding moieties fused to them (similar to natural antibodies, except that the two arms bind different antigenic targets or epitopes). The antigen-binding moieties can be single-domain antibodies, single-chain antibodies (scFv), or Fab fragments. The Fc fragments can contain mutations that ensure heavy chain heteropolymerization; KIH (knob-in-hole) technology is one strategy to address heavy chain heteropolymerization. Typically, KIH technology involves modifying the amino acid sequence of the CH3 region to create a structure that facilitates the pairing of heterologous half-antibodies, thus forming a bispecific antibody while preserving as much of the normal antibody structure as possible. For guidance on KIH technology, see, for example, "An efficient route to human bispecific IgG," A. Margaret Merchant et al., Nature Biotechnology, Volume 16, 1998.

[0014] The full text of that document is incorporated into this paper through citation.

[0105] In the construction of bispecific antibodies, "antigen-binding fragments" include, but are not limited to, single-domain antibody forms, Fab fragment forms, and / or single-chain antibody (scFv) forms.

[0106] As used herein, the term "single-domain antibody" refers to a naturally occurring heavy chain monovariable domain antibody lacking the light chain. Such antibodies contain a heavy chain variable region (VHH) and conventional CH2 and CH3 regions (e.g., one or two groups of regions: the heavy chain variable region (VHH) and conventional CH2 and CH3 regions). The VHH structure, cloned and expressed independently, possesses structural stability and antigen-binding activity comparable to the original heavy chain antibody and is the smallest known unit capable of binding to a target antigen. Single-domain antibodies are also known as nanobodies (Nb).

[0107] As used herein, the terms “Fab (fragment antigen binding) fragment,” “Fab portion,” or similar terms refer to antibody fragments that bind to antigens produced by treating an intact antibody with papain, including the intact light chain (VL-CL), the heavy chain variable region, and the CH1 fragment (VH-CH1).

[0108] As used in this article, "single-chain antibody (scFv, single-chain fragment variable)" refers to an antibody with a single-chain structure, typically constructed using genetic engineering techniques. It is a polypeptide chain containing a heavy chain variable region (VH) and a light chain variable region (VL). A flexible linker is usually designed between the heavy and light chain variable regions so that they can fold into the correct conformation to bind the antigen.

[0109] As used herein, the terms “Fc fragment,” “Fc domain,” and “Fc portion” are used interchangeably to refer to a portion of the antibody heavy chain constant region, including the hinge region, the CH2 and CH3 fragments of the heavy chain constant region, and are determined with reference to the EU numbering of human IgG1 antibodies.

[0110] As used in this article, "specific binding" refers to a non-random binding reaction between two molecules, such as the binding of an antibody to an antigenic epitope.

[0111] As used herein, the term "tumor" refers to a growth or solid lesion formed by abnormal cell growth. Tumors can be benign, pre-malignant, or malignant. In some embodiments of this application, the tumor is selected from acute myeloid leukemia, pancreatic cancer, cervical cancer, ovarian cancer, lung cancer, liver cancer, breast cancer, and colon cancer. In some specific embodiments, the tumor is acute myeloid leukemia.

[0112] As used herein, "HLA-A02 / NDC80 positive tumor" refers to a tumor or cancer that simultaneously expresses HLA-A02 and NDC80. NDC80 is a kinetocyte protein not expressed on the surface of tumor cells. It requires HLA-A02 molecules to present the NDC80 epitope peptide (e.g., ALNEQIARL) to the tumor cell surface, thereby enabling antibody recognition of NDC80. Therefore, identifying "HLA-A02 / NDC80 positive tumors" can be achieved by detecting the presence of both HLA-A02 molecules and NDC80 protein in cells, or by detecting the presence of a complex formed by HLA-A02 molecules and the NDC80 epitope peptide. The presence of both HLA-A02 molecules and NDC80 protein can be detected using techniques known in the art, such as flow cytometry, ELISA, and nucleic acid probes. The presence of a complex formed by HLA-A02 molecules and the NDC80 epitope peptide can be detected using techniques known in the art, such as immunoprecipitation and LC-MS / MS.

[0113] EC 50EC50 primarily refers to the concentration of a drug, antibody, or toxin that, after a specific exposure time, achieves 50% of its maximum biological effect. In pharmaceutical science, besides characterizing the activation capacity of agonists in in vitro experiments, it can also be used to indicate the blood drug concentration required to achieve half of the maximum biological effect in vivo. In some literature, EC50... 50 It is also used to characterize the potency of a compound at the cellular level (including agonist and antagonist), and can be measured by methods such as ELISA to determine EC. 50 value.

[0114] The term "identity / homology / consistency" in relation to amino acid or nucleic acid sequences is defined as the percentage of identical residues in an amino acid or nucleotide sequence variant after sequence alignment and vacancy introduction, reaching the maximum percentage of identity if desired. The methods and computer programs used for alignment are well known in the art.

[0115] In one aspect, this application provides a bispecific antibody comprising a first antigen-binding fragment that binds to the HLA-A02 / NDC80 complex and a second antigen-binding fragment that binds to activated T-cell antigens.

[0116] In some embodiments of the first aspect, the bispecific antibody is capable of mediating HLA-A02. + / NDC80 + Tumor cells activate T cells, and / or the bispecific antibody can mediate PBMC killing of HLA-A02. + / NDC80 + Tumor cells. For example, the bispecific antibody can mediate HLA-A02. + / NDC80 + Tumor cells activate Jurkat-Dual cells.

[0117] In some embodiments of the first aspect, the binding epitope of the first antigen-binding fragment to the HLA-A02 / NDC80 complex includes one or more residues from positions 274-282 (SEQ ID NO:1) of NDC80 as shown in SEQ ID NO:2. In some specific embodiments, the binding epitope of the first antigen-binding fragment to the HLA-A02 / NDC80 complex includes at least one of residues from positions 275, 276, 278, 279, and 280 of NDC80 as shown in SEQ ID NO:2.

[0118] In some embodiments of the first aspect, the first antigen-binding fragment comprises HCDR1 as shown in SEQ ID NO:18, HCDR2 as shown in SEQ ID NO:19, and HCDR3 as shown in SEQ ID NO:20, wherein the amino acid sequence of HCDR is defined according to the Kabat scheme.

[0119] In some embodiments of the first aspect, the first antigen-binding fragment is in the form of a single-domain antibody. For example, the first antigen-binding fragment comprises a monovalent or multivalent (e.g., 1, 2, 3, 4, 5, or 6-valent) single-domain antibody that binds the HLA-A02 / NDC80 complex. In some specific embodiments, the first antigen-binding fragment comprises a monovalent single-domain antibody that binds the HLA-A02 / NDC80 complex. In some specific embodiments, the first antigen-binding fragment comprises a bivalent single-domain antibody that binds the HLA-A02 / NDC80 complex.

[0120] In some embodiments, the first antigen-binding fragment comprises heavy chain variable regions of two monovalent single-domain antibodies that bind to the HLA-A02 / NDC80 complex.

[0121] In some embodiments of the first aspect, the first antigen-binding fragment comprises the heavy chain variable region of two directly fused monovalent single-domain antibodies that bind to the HLA-A02 / NDC80 complex.

[0122] In some embodiments of the first aspect, the first antigen-binding fragment comprises heavy chain variable regions of two monovalent single-domain antibodies binding the HLA-A02 / NDC80 complex, linked by a linker. In some embodiments, the linker is a GS-type flexible peptide linker. In some embodiments, the linker is (G4S)n, (SG4)n, or G4(SG4)n, where n is an integer from 1 to 10, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or an integer or range of any two of the above values. In some embodiments, the linker is (G4S)n, (SG4)n, or G4(SG4)n, where n is an integer from 2 to 4, such as 2, 3, or 4.

[0123] In some embodiments of the first aspect, the activating T-cell antigen is a CD3 molecule.

[0124] In some embodiments of the first aspect, the second antigen-binding fragment comprises HCDR1 as shown in SEQ ID NO:30, HCDR2 as shown in SEQ ID NO:31, HCDR3 as shown in SEQ ID NO:32, LCDR1 as shown in SEQ ID NO:34, LCDR2 as shown in SEQ ID NO:35, and LCDR3 as shown in SEQ ID NO:36, wherein the amino acid sequences of HCDR and LCDR are defined according to the Kabat scheme.

[0125] In some embodiments of the first aspect, the second antigen-binding fragment is in the form of a single-chain antibody (scFv) or a Fab fragment. In some specific embodiments, the second antigen-binding fragment is in the form of scFv.

[0126] In some embodiments of the first aspect, the first antigen-binding fragment comprises a heavy chain variable region as shown in SEQ ID NO:17 or 27, and / or the second antigen-binding fragment comprises a heavy chain variable region as shown in SEQ ID NO:29 and a light chain variable region as shown in SEQ ID NO:33.

[0127] For example, the first antigen-binding fragment may include a heavy chain variable region as shown in SEQ ID NO:17, and the second antigen-binding fragment may include a heavy chain variable region as shown in SEQ ID NO:29 and a light chain variable region as shown in SEQ ID NO:33. Alternatively, the first antigen-binding fragment may include a heavy chain variable region as shown in SEQ ID NO:27, and the second antigen-binding fragment may include a heavy chain variable region as shown in SEQ ID NO:29 and a light chain variable region as shown in SEQ ID NO:33.

[0128] In some embodiments of the first aspect, the first antigen-binding fragment comprises a heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:17 or 27.

[0129] In some embodiments of the first aspect, the amino acid sequence of the first antigen-binding fragment may be substituted, deleted, and / or added by approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids different from the amino acid sequence shown in SEQ ID NO: 17 or 27.

[0130] In some embodiments of the first aspect, the amino acid sequence of the first antigen-binding fragment may have at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher homology with the amino acid sequence shown in SEQ ID NO:17 or 27.

[0131] In some embodiments of the first aspect, the C-terminal or N-terminal region of the amino acid sequence shown in SEQ ID NO:17 or 27 may be truncated by about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25 or more amino acids while still retaining the function of a similar first antigen-binding fragment.

[0132] In some embodiments of the first aspect, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25 or more amino acids may be added to the C-terminal or N-terminal region of the amino acid sequence shown in SEQ ID NO: 17 or 27, and the resulting amino acid sequence still retains a similar function to the first antigen-binding fragment.

[0133] In some embodiments of the first aspect, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25 or more amino acids may be added or deleted in regions other than the C-terminus or N-terminus of the amino acid sequence shown in SEQ ID NO: 17 or 27, as long as the altered amino acid sequence substantially maintains the function of the first antigen-binding fragment.

[0134] In some embodiments of the first aspect, the second antigen-binding fragment comprises a heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:29 and a light chain variable region with an amino acid sequence as shown in SEQ ID NO:33.

[0135] In some embodiments of the first aspect, the amino acid sequence of the heavy chain variable region of the second antigen-binding fragment may be substituted, deleted, and / or added with approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids different from the amino acid sequence shown in SEQ ID NO:29.

[0136] In some embodiments of the first aspect, the amino acid sequence of the heavy chain variable region of the second antigen-binding fragment may have at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher homology with the amino acid sequence shown in SEQ ID NO:29.

[0137] In some embodiments of the first aspect, the C-terminal or N-terminal region of the amino acid sequence shown in SEQ ID NO:29 may also be truncated by about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25 or more amino acids, while still retaining the function of the heavy chain variable region of the second antigen-binding fragment.

[0138] In some embodiments of the first aspect, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25 or more amino acids may be added to the C-terminal or N-terminal region of the amino acid sequence shown in SEQ ID NO:29, and the resulting amino acid sequence still retains the function of the heavy chain variable region of the second antigen-binding fragment.

[0139] In some embodiments of the first aspect, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25 or more amino acids may be added or deleted in regions other than the C-terminus or N-terminus of the amino acid sequence shown in SEQ ID NO:29, as long as the altered amino acid sequence substantially maintains the function of the heavy chain variable region of the second antigen-binding fragment.

[0140] In some embodiments of the first aspect, the amino acid sequence of the light chain variable region of the second antigen-binding fragment may be substituted, deleted, and / or added by approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids different from the amino acid sequence shown in SEQ ID NO:33.

[0141] In some embodiments of the first aspect, the amino acid sequence of the light chain variable region of the second antigen-binding fragment may have at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher homology with the amino acid sequence shown in SEQ ID NO:33.

[0142] In some embodiments of the first aspect, the C-terminal or N-terminal region of the amino acid sequence shown in SEQ ID NO:33 may also be truncated by about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25 or more amino acids, while still retaining the function of a similar light chain variable region of the second antigen-binding fragment.

[0143] In some embodiments of the first aspect, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25 or more amino acids may be added to the C-terminal or N-terminal region of the amino acid sequence shown in SEQ ID NO:33, and the resulting amino acid sequence still retains the function of the light chain variable region similar to that of the second antigen-binding fragment.

[0144] In some embodiments of the first aspect, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25 or more amino acids may be added or deleted in regions other than the C-terminus or N-terminus of the amino acid sequence shown in SEQ ID NO:33, as long as the altered amino acid sequence substantially maintains the function of the light chain variable region of the second antigen-binding fragment.

[0145] In some embodiments of the first aspect, the first antigen-binding fragment and the second antigen-binding fragment are linked by an Fc fragment of the antibody heavy chain constant region.

[0146] In some specific embodiments of the first aspect, the antibody heavy chain constant region Fc fragment includes a first Fc fragment and a second Fc fragment, one of the first Fc fragment and the second Fc fragment (e.g., at its C-terminus) is linked to the first antigen-binding fragment, and the other of the first Fc fragment and the second Fc fragment (e.g., at its C-terminus) is linked to the second antigen-binding fragment.

[0147] The Fc fragment of the antibody heavy chain constant region can be an Fc fragment of the IgG1 subtype. In some specific embodiments, the Fc fragment of the antibody heavy chain constant region can be an Fc fragment of the IgG1m3 subtype.

[0148] In some embodiments, the constant region of the antibody heavy chain of the bispecific antibody may be human IgG1 subtype (SEQ ID NO:8) or various mutants of selected human IgG1 subtypes, such as: IgG1H (SEQ ID NO:9), IgG1K (SEQ ID NO:10), IgG1m3-H (SEQ ID NO:11), IgG1m3-K (SEQ ID NO:12), IgG1m3-H1n1 (SEQ ID NO:13) or IgG1m3-Kn1 (SEQ ID NO:14), and the constant region of the light chain may be human λ subtype (SEQ ID NO:15) or human κ subtype (SEQ ID NO:16).

[0149] In some specific embodiments of the first aspect, one of the first Fc fragment and the second Fc fragment comprises amino acid C at position 354 and amino acid W at position 366, and the other of the first Fc fragment and the second Fc fragment comprises amino acid C at position 349, amino acid S at position 366, amino acid A at position 368 and amino acid V at position 407, wherein the amino acid positions of the antibody constant region are determined according to EU numbering.

[0150] In some specific embodiments of the first aspect, the first Fc fragment and the second Fc fragment comprise amino acid F at position 234, amino acid E at position 235, and amino acid S at position 331, wherein the amino acid positions in the antibody constant region are determined according to EU numbering.

[0151] In some embodiments of the first aspect, the bispecific antibody comprises a first arm that binds to the HLA-A02 / NDC80 complex and a second arm that binds to an activated T-cell antigen, wherein

[0152] The first arm comprises an amino acid sequence as shown in SEQ ID NO:39 or 40; and

[0153] The second arm contains an amino acid sequence as shown in SEQ ID NO:41.

[0154] Secondly, this application provides a single-domain antibody that binds to the HLA-A02 / NDC80 complex, which contains

[0155] HCDR1, as shown in SEQ ID NO:18,

[0156] HCDR2, as shown in SEQ ID NO:19, and

[0157] HCDR3, as shown in SEQ ID NO:20;

[0158] The amino acid sequence of HCDR is defined according to the Kabat scheme.

[0159] In some embodiments of the first aspect, the binding epitope of the first antigen-binding fragment to the HLA-A02 / NDC80 complex includes one or more residues from positions 274-282 (SEQ ID NO:1) of NDC80 as shown in SEQ ID NO:2. In some specific embodiments, the binding epitope of the first antigen-binding fragment to the HLA-A02 / NDC80 complex includes at least one of residues from positions 275, 276, 278, 279, and 280 of NDC80 as shown in SEQ ID NO:2.

[0160] In some embodiments of the second aspect, the single-domain antibody is a monovalent or multivalent (e.g., 1, 2, 3, 4, 5, or 6-valent) single-domain antibody form that binds to the HLA-A02 / NDC80 complex.

[0161] In some specific embodiments of the second aspect, the single-domain antibody comprises the heavy chain variable region of two directly fused monovalent forms of single-domain antibodies binding the HLA-A02 / NDC80 complex.

[0162] In some specific embodiments of the second aspect, the single-domain antibody comprises the heavy chain variable region of two monovalent single-domain antibodies binding the HLA-A02 / NDC80 complex, linked by a linker. In some embodiments, the linker is a GS-type flexible peptide linker. In some embodiments, the linker is (G4S)n, (SG4)n, or G4(SG4)n, where n is an integer from 1 to 10, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or an integer or range of any two of the above values. In some embodiments, the linker is (G4S)n, (SG4)n, or G4(SG4)n, where n is an integer from 2 to 4, such as 2, 3, or 4.

[0163] In some embodiments of the second aspect, the single-domain antibody comprises a heavy chain variable region amino acid sequence as shown in SEQ ID NO:17 or 27.

[0164] In some embodiments of the second aspect, the amino acid sequence of the single-domain antibody may be substituted, deleted, and / or added with approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids different from the amino acid sequence of the heavy chain variable region shown in SEQ ID NO:17 or 27.

[0165] In some embodiments of the second aspect, the amino acid sequence of the single-domain antibody may have at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher homology with the heavy chain variable region amino acid sequence shown in SEQ ID NO:17 or 27.

[0166] In some embodiments of the second aspect, the C-terminal or N-terminal region of the heavy chain variable region amino acid sequence shown in SEQ ID NO:17 or 27 may be truncated by about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25 or more amino acids while still maintaining similar functions to the single-domain antibody.

[0167] In some embodiments of the second aspect, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25 or more amino acids may be added to the C-terminal or N-terminal region of the heavy chain variable region amino acid sequence shown in SEQ ID NO: 17 or 27, and the resulting amino acid sequence still maintains a similar function to the single-domain antibody.

[0168] In some embodiments of the second aspect, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25 or more amino acids may be added or deleted in regions other than the C-terminus or N-terminus of the heavy chain variable region amino acid sequence shown in SEQ ID NO: 17 or 27, provided that the altered amino acid sequence substantially maintains a similar function to the single-domain antibody.

[0169] Thirdly, this application provides a nucleic acid molecule that encodes the bispecific antibody described in the first aspect or the single-domain antibody described in the second aspect.

[0170] In some embodiments of the third aspect, the nucleic acid molecule may include DNA molecules and RNA molecules. The nucleic acid molecule may be single-stranded or double-stranded, and may be cDNA.

[0171] In some embodiments of the third aspect, the nucleic acid molecule is operatively linked to a regulatory sequence that can be recognized by a host cell transformed with the vector. The host cell is, for example, a mammalian cell.

[0172] This application provides combinations of polynucleotides, the combinations comprising a polynucleotide encoding a light chain of a bispecific antibody of this application or an antigen-binding moiety thereof, and a polynucleotide encoding a heavy chain of a bispecific antibody of this application or an antigen-binding moiety thereof.

[0173] This application provides vectors (e.g., expression vectors) containing the nucleic acid molecules or combinations of polynucleotides described in the second aspect. In some embodiments, the expression vectors of this application comprise the nucleic acid molecules or combinations of polynucleotides described in this application, wherein the polynucleotides are efficiently linked to a regulatory sequence that allows the polypeptides they encode to be expressed in a host cell or cell-free expression system. The choice of expression vector depends on the choice of host cell and can be selected to achieve the desired expression and regulatory characteristics in the selected host cell.

[0174] An "expression vector" is a vector that includes one or more expression control sequences. An "expression control sequence" is a DNA sequence that controls and regulates the transcription and / or translation of another DNA sequence.

[0175] The nucleic acid in the vector can be operatively linked to one or more expression control sequences. As used herein, "operatively linked" means incorporated into the genetic construct such that the expression control sequence effectively controls the expression of the target coding sequence. Examples of expression control sequences include promoters, enhancers, and transcription termination regions. A promoter is an expression control sequence consisting of a region of the DNA molecule typically located within 100 nucleotides upstream of the transcription start site (usually near the start site of RNA polymerase II). For the coding sequence to be under the control of the promoter, the translation start site of the polypeptide translation reading frame must be located between 1 and 50 nucleotides downstream of the promoter. Enhancers provide expression specificity in terms of time, location, and level. Unlike promoters, enhancers can function at different distances from the transcription start site. Enhancers can also be located downstream of the transcription start site. When RNA polymerase is able to transcribe the coding sequence into mRNA, and then the mRNA can be translated into the protein encoded by the coding sequence, the coding sequence is "operatively linked" to and "under the control" of the expression control sequence in the cell.

[0176] Suitable expression vectors include, but are not limited to, plasmids and viral vectors derived from, for example, bacteriophages, baculoviruses, tobacco mosaic virus, herpesviruses, cytomegaloviruses, retroviruses, vaccinia virus, adenoviruses, and adeno-associated viruses. Many vectors and expression systems are commercially available from companies such as Novagen (Madison, WI), Clontech (Palo Alto, CA), Stratagene (LaJolla, CA), and Invitrogen Life Technologies (Carlsbad, CA).

[0177] Expression vectors may include tag sequences. Tag sequences are typically expressed as a fusion with the encoded polypeptide. Such tags can be inserted at any position within the polypeptide, including the carboxyl or amino terminus. Examples of useful tags include, but are not limited to, Fc fragments, polyhistidine, green fluorescent protein (GFP), glutathione S-transferase (GST), c-myc, hemagglutinin, Flag™ tags (Kodak, New Haven, CT), maltose E-binding protein, and protein A. In some embodiments, the nucleic acid molecule encoding the antibody of this application is contained in a vector of nucleic acid encoding one or more domains of the Ig heavy chain constant region, said domains being, for example, amino acid sequences corresponding to the hinge region, CH2 region, and CH3 region of the human immunoglobulin Cγ1 chain (Fc fragment).

[0178] This application provides a host cell containing the nucleic acid molecules or vectors described in the second aspect. In some embodiments of this application, the host cell may be a prokaryotic host cell, a eukaryotic host cell, or a bacteriophage. The prokaryotic host cell may be *Escherichia coli* (e.g., *E. coli* cells well-known in the art such as DH5α and BL21), *Bacillus subtilis*, *Streptomyces*, or *Proteus mirabilis*. The eukaryotic host cell may be a fungus such as *Pichia pastoris*, *Saccharomyces cerevisiae*, *Schizosaccharizoa*, *Trichoderma*, etc.; an insect cell such as *Ardisia crenata*; a plant cell such as tobacco; or a mammalian cell such as HEK293F, BHK cells, CHO cells, COS cells, or myeloma cells. In some embodiments, the host cell described in this application is preferably a mammalian cell, more preferably HEK293F, BHK cells, CHO cells, NSO cells, or COS cells.

[0179] Fourthly, this application provides a pharmaceutical composition comprising the bispecific antibody described in the first aspect or the single-domain antibody described in the second aspect, as well as a pharmaceutically acceptable excipient, diluent, or carrier.

[0180] In some embodiments of the fourth aspect, the pharmaceutical composition is used for the prevention or treatment of HLA-A02 / NDC80 positive tumors.

[0181] In some embodiments of the fourth aspect, the pharmaceutical composition may further comprise one or more of the following: lubricants, such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifiers; suspending agents; preservatives, such as benzoic acid, sorbic acid, and calcium propionate; sweeteners and / or flavoring agents, etc.

[0182] In some embodiments of the fourth aspect, the pharmaceutical composition of this application may be formulated as tablets, pills, powders, lozenges, elixirs, suspensions, emulsions, solutions, syrups, suppositories, or capsules.

[0183] In some embodiments of the fourth aspect, the pharmaceutical composition of this application may be delivered using any physiologically acceptable method of administration, including but not limited to: oral administration, parenteral administration, nasal administration, rectal administration, intraperitoneal administration, intravascular injection, subcutaneous administration, transdermal administration, inhalation administration, etc.

[0184] In some embodiments of the fourth aspect, a pharmaceutical composition for therapeutic use can be formulated for storage by mixing a reagent of the desired purity with, as appropriate, a pharmaceutically acceptable carrier, excipient, etc., in the form of a lyophilized formulation or an aqueous solution.

[0185] Fifthly, this application provides the use of the bispecific antibody described in the first aspect, the single-domain antibody described in the second aspect, or the pharmaceutical composition described in the fourth aspect in the preparation of a medicament for the prevention or treatment of HLA-A02 / NDC80 positive tumors.

[0186] In a sixth aspect, this application provides a method for preventing or treating HLA-A02 / NDC80 positive tumors, the method comprising administering to a subject in need an effective amount of the bispecific antibody of the first aspect, the single-domain antibody of the second aspect, or the pharmaceutical composition of the fourth aspect.

[0187] In some embodiments of the fifth and / or sixth aspects, the HLA-A02 / NDC80 positive tumor is selected from: acute myeloid leukemia, pancreatic cancer, cervical cancer, ovarian cancer, lung cancer, liver cancer, breast cancer, and colon cancer. Preferably, the HLA-A02 / NDC80 positive tumor is acute myeloid leukemia.

[0188] In other aspects, this application also provides nucleic acid molecules encoding the antibody of the present invention or its light or heavy chain or its antigen-binding portion, a vector comprising the nucleic acid molecule, a host cell comprising the nucleic acid molecule or the vector, and a method for producing the antibody and / or its antigen-binding portion. In some embodiments, the nucleic acid molecule is operatively linked to a regulatory nucleotide sequence that can be recognized by a host cell transformed with the vector. In some embodiments, the method for producing the antibody or its antigen-binding portion includes culturing host cells to express the nucleic acid. In some embodiments, the method for producing the antibody or its antigen-binding portion further includes recovering the antibody or its antigen-binding portion from a host cell culture medium.

[0189] It should be understood that the above detailed description is only intended to provide a clearer understanding of the contents of this application to those skilled in the art, and is not intended to limit in any way. Those skilled in the art can make various modifications and variations to the described embodiments.

[0190] The following examples are for illustrative purposes only and are not intended to limit the scope of this application.

[0191] Example

[0192] Example 1: Preparation of recombinant protein

[0193] In the preparation of bispecific antibodies targeting HLA-A02 / NDC80 and CD3, several different recombinant proteins are required, including the extracellular domain of human CD3E (hCD3E, SEQ ID NO:3) and the extracellular domain of human CD3D (hCD3D, SEQ ID NO:4). Meanwhile, referring to the literature Kotsiou E, Brzostek J, Lenart I, Antoniou AN, Dyson J, Gould KG. Dimerization of soluble disulfide trap single-chain major histocompatibility complex class I molecules dependent on peptide binding affinity. Antioxid Redox Signal. 2011 Aug 1; 15(3):635-44

[0015] A disulfide trap single-chain trimer (dtSCT) complex containing the NDC80 antigenic peptide ALNEQIARL (SEQ ID NO:1) and HLA-A0201 was prepared (MIP-N1-A0201, SEQ ID NO:5). Additionally, disulfide trap single-chain trimer complexes MIP-N1-A0203 (SEQ ID NO:89), MIP-N1-A0206 (SEQ ID NO:90), and MIP-N1-A0207 (SEQ ID NO:91) containing the NDC80 antigenic peptide ALNEQIARL (SEQ ID NO:1) and HLA-A0203 / A0206 / A0207 were prepared. These recombinant proteins all exhibit numerous post-translational modifications, thus utilizing mammalian cell expression systems is advantageous for maintaining the structure and function of the recombinant proteins. Adding a His tag (His, SEQ ID NO:6) or the Fc segment of mouse antibody IgG2a (mFc, SEQ ID NO:7) to the C-terminus of recombinant proteins is beneficial for the purification of recombinant proteins and the identification of monoclonal antibody functions.

[0194] Based on the amino acid sequences of various target recombinant proteins from the Uniprot database, genes for the aforementioned recombinant proteins (containing His tags or mFc encoding genes) were designed and synthesized. The synthesized recombinant protein genes were cloned into suitable eukaryotic expression vectors (Invitrogen's pcDNA3.1), and then the prepared recombinant protein expression plasmids were transfected into HEK293 cells (Invitrogen's HEK293F) using liposomes (Invitrogen's 293fectin) or other cationic transfection reagents (PEI). The cells were cultured in serum-free suspension for 3-4 days. The culture supernatant was then harvested by centrifugation.

[0195] His-tagged fusion-expressed recombinant proteins were purified in one step from the culture supernatant using a metal chelate affinity chromatography column (GE's HisTrap FF). mFc fusion-expressed recombinant proteins were purified in one step using a Protein A / G affinity chromatography column (GE's Mabselect SURE). The recombinant protein storage buffer was then replaced with PBS (pH 7.0) using a desalting column (GE's Hitrap desaulting). If necessary, the recombinant protein samples could be filtered sterilized and then aliquoted and stored at -20°C.

[0196] Example 2: Screening for antibodies binding to the HLA-A02 / NDC80 complex from a llama immune bank

[0197] 2.1 Construction of the Camel Immunity Bank

[0198] One healthy adult llama was selected, and blood was collected to obtain baseline serum before immunization. For the first immunization, 0.4 mg of MIP-N1-A0201-His fusion protein was emulsified with Freund's complete adjuvant and injected subcutaneously at multiple sites. Two weeks later, booster immunizations were performed, with 0.4 mg of MIP-N1-A0201-His fusion protein emulsified with Freund's incomplete adjuvant and injected subcutaneously at multiple sites. A total of 5 booster immunizations were performed, with blood collected before each immunization for antibody titer analysis. For the seventh immunization, no adjuvant was added, and 0.4 mg of MIP-N1-A0201-His fusion protein was used as the antigen and injected subcutaneously at multiple sites for pulse immunization. Three days later, 150 mL of peripheral blood was collected for lymphocyte separation. Lymphocytes were isolated from 150 mL of llama peripheral blood using a camel peripheral blood lymphocyte isolation kit (Solarbio, CAT#P5750). Total RNA was extracted from the lymphocytes using a total RNA extraction kit (Tiangen, CAT#DP430). Using the extracted total RNA as a template, the variable region of the camel heavy chain was synthesized using a first-strand cDNA synthesis kit (Thermo Scientific, CAT#K1621). Gene-specific primers were used for reverse transcription, with the primer pairing region located in the CH2 domain of the antibody heavy chain constant region. The specific primer sequence was PCal-CH2R: TCCTTCCCCGTCAGCCAGTCCT (SEQ ID NO:86). The synthesized cDNA was immediately stored at -70℃ for later use. Then, using the cDNA obtained from reverse transcription as a template, [reference missing]. E, Poignavent V, Vincke C, Ritzenthaler C, Muyldermans S, Monsion B. Construction of High-Quality Camel Immune Antibody Libraries. Methods Mol Biol. 2018; 1701:169-187

[0016] Primers were synthesized, and the camel VHH gene was isolated by nested PCR amplification. Finally, the amplified VHH gene was cloned into the vector pADSCFV-S (see Chinese Invention Patent Application Publication CN105315371A).

[0017] A VHH library was constructed. This antibody library has a size of 2.38E8 and an accuracy of 50%.

[0199] 2.2 Screening of the camel immune bank

[0200] Using the recombinant MIP-N1-A0201-His prepared in Example 1 as the antigen, a solid-phase screening strategy was employed (experimental protocol referenced from Phage Display: A Universal Laboratory Guide / edited by Clackson, T., and Lowman, HB; translated by Ma Lan et al., Chemical Industry Press, 2008.5).

[0018] The phage library displaying camel single-domain antibodies constructed in Example 2.1 was screened through three rounds of screening: binding, elution, neutralization, infection, and amplification. Finally, the TCRm (TCR mimic) antibody N2G1 that specifically binds to MIP-N1-A0201 was obtained.

[0201] The nucleotide sequence encoding the N2G1 heavy chain variable region (SEQ ID NO: 17) was cloned into a eukaryotic expression vector (Invitrogen's pcDNA3.1) fused with the Fc segment encoding the human antibody IgG1m3 to express the N2G1-G1m3-Fc recombinant protein. Simultaneously, a DP47 (germline gene antibody, according to US patent application US2016 / 0200833 A1) was prepared.

[0019] The amino acid sequence of VH of DP47 is shown in SEQ ID NO:21; the amino acid sequence of VK of DP47 is shown in SEQ ID NO:22) The monoclonal antibody DP47-IgG1 was used as a negative control.

[0202] Example 3: Identification of TCRm antibodies binding to the HLA-A02 / NDC80 complex

[0203] 3.1 Binding of anti-HLA-A02 / NDC80 complex TCRm antibody to MIP-N1-A0201-His recombinant protein

[0204] The prepared MIP-N1-A0201-His was coated onto 96-well plates (1 μg / ml, 100 μL / well) and incubated overnight at 4°C. Blocking was performed using PBS-0.1% Tween 20-3% skim milk blocking buffer at 37°C for 1 hour. The TCRm antibody against the HLA-A02 / NDC80 complex was serially diluted with PBS, starting at 20 μg / mL, with 11 4-fold serial dilutions, and 100 μL / well was added to each well of the blocked 96-well ELISA plate. The plates were incubated at 37°C for 1 hour. The ELISA plates were washed with PBS-0.1% Tween 20, and HRP-labeled mouse anti-human IgG monoclonal antibody (Beijing Bio-Sens Biotechnology Co., Ltd., bsm-0297M-HRP) was added, followed by incubation at 37°C for 1 hour. The ELISA plate was washed with PBS-0.1% Tween 20, and OPD substrate chromogenic solution was added. After 5-10 minutes, the chromogenic reaction was terminated with 1M H2SO4. The optical density was measured at dual wavelengths of 492nm / 630nm using a microplate reader. The results are shown in Figure 1. N2G1 specifically binds to MIP-N1-A0201, that is, N2G1 specifically binds to the HLA-A02 / NDC80 complex.

[0205] 3.2 Affinity analysis of anti-HLA-A02 / NDC80 complex TCRm antibody

[0206] The affinity of the TCRm antibody N2G1 against the HLA-A02 / NDC80 complex was determined using surface plasmon resonance (SPR) technology with a Biacore T200. The amino-coupled antibody kit (BR100050), human antibody capture kit (29234600), Series S sensor chip CM5 (29149603), and 10×HBS-EP (BR100669) at pH 7.4, along with related reagents and consumables, were all purchased from Cytiva. Following the kit instructions, the carboxylated CM5 chip surface was activated with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS). The anti-human IgG (Fc) antibody (capture antibody) was then used with 10 mM... Diluted to 25 μg / mL with sodium acetate at pH 5.0, the antibody was injected at a flow rate of 10 μL / min to achieve a conjugation volume of approximately 10,000 response units (RU). Following the injection of the capture antibody, 1M ethanolamine was injected to block unreacted groups. For kinetic measurements, the TCRm antibody N2G1-Fc was diluted to 1 μg / mL and injected at a flow rate of 10 μL / min to ensure that approximately 100 RU of antibody was captured by the anti-human Fc antibody. Then, a series of concentration gradients (1.23 nM, 3.7 nM, 11.1 nM, 33.3 nM, 100 nM) of MIP-N1-A0201-His were set and injected at 25°C at a flow rate of 30 μL / min from low to high concentrations, with a binding time of 60 s and a dissociation time of 1200 s. The chip surface was regenerated by injecting 3M MgCl2 solution at a flow rate of 10 μL / min for 30 s. Biacore was used. The T200 evaluation software version 3.0 calculates the binding rate (Ka) and dissociation rate (Kd) by fitting binding and dissociation sensor maps using a 1:1 model. The dissociation equilibrium constant (KD) is calculated using the ratio Kd / Ka. The fitting results are shown in Table 1.

[0207] Table 1. Affinity of TCRm antibody N2G1 against MIP-N1-A0201 for the anti-HLA-A02 / NDC80 complex.

[0208] 3.3 Binding activity of anti-HLA-A02 / NDC80 complex TCRm antibody to T2 cells induced by antigen peptide pulses

[0209] Collect T2 cells (human lymphoma cells, HLA-A02) in the logarithmic growth phase. + Purchased from Shanghai Hongshun Biotechnology Co., Ltd., the sample was centrifuged and resuspended in growth medium to a concentration of 1×10⁻⁶.6 / mL, 1mL per well in a 24-well plate. Chemically synthesized peptide NDC80 274- 282 (ALNEQIARL) (Genscript Biotech Inc.), and added to a final concentration of 50 μg / mL into 24-well plates, incubated overnight. After 16 hours, centrifuged, and resuspended in PBS buffer containing 1% BSA to a final volume of 2 × 10⁻⁶. 6 100 μL of N2G1 antibody and DP47-IgG1 negative control were seeded into each well of a 96-well V plate and centrifuged, then the supernatant was discarded. Antibody N2G1 and negative control DP47-IgG1 were prepared into 100 nM initial concentrations and 4-fold dilutions using PBS, for a total of 10 concentrations. 100 μL of each sample was added to the wells containing cells and incubated at 4°C for 1 hour. The cells were then washed three times with 200 μL of PBS and incubated with goat anti-human IgG-FITC (Beijing Zhongshan Jinqiao Biotechnology Co., Ltd., ZF-0308) at 100 μL per well, incubated at 4°C in the dark for 30 minutes. The cells were then washed three times with 200 μL of PBS, resuspended in 100 μL of PBS, and the FITC channels were detected by flow cytometry (ACEA, Novocyte). The results are shown in Figure 2. N2G1 specifically binds to the antigenic peptide NDC80. 274-282 (ALNEQIARL) pulses in T2 cells, namely N2G1 binding to the HLA-A02 / NDC80 complex on the cell surface.

[0210] 3.4 Analysis of key amino acid binding of anti-HLA-A02 / NDC80 complex TCRm antibody

[0211] Chemical synthesis NDC80 274-282 (ALNEQIARL) alanine scanning mutant peptides (SEQ ID NO:42-50, namely NDC80-A1G, NDC80-L2A, NDC80-N3A, NDC80-E4A, NDC80-Q5A, NDC80-I6A, NDC80-A7G, NDC80-R8A and NDC80-L9A in Figure 3, respectively). Refer to Example 3.3 for the detection of N2G1 and NDC80. 274-282 Binding of the alanine-scanning mutant peptide (ALNEQIARL) to T2 cells was measured. The binding of N2G1 to the alanine-scanning mutant peptide was calculated relative to the original peptide. The results are shown in Figure 3, NDC80. 274-282 When alanine is substituted at positions 2, 3, 4, 5, 6, and 7 of (ALNEQIARL) (i.e., "NDC80" in Figure 3), the binding affinity of TCRm antibody N2G1 decreases by 80% or more, i.e., NDC80... 274-282 The 2nd, 3rd, 4th, 5th, 6th, and 7th amino acids of (ALNEQIARL) are key amino acids for N2G1 binding.

[0212] Example 4: Humanization and identification of TCRm antibody against HLA-A02 / NDC80 complex

[0213] 4.1 Humanization of TCRm antibody against HLA-A02 / NDC80 complex

[0214] Humanization of the TCRm antibody N2G1 was studied to reduce its immunogenicity. The humanization protocol adopted the classic framework grafting strategy (see Tan P, Mitchell DA, Buss TN, Holmes MA, Anasetti C, Foote J. "Superhumanized" antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28. J Immunol. 2002 Jul 15;169(2):1119-25).

[0020] The amino acid sequence of N2G1 was compared with human antibody germline gene sequences in the IMGT database. Suitable germline gene sequences were selected to provide frame regions 1 to 3 (FR1+FR2+FR3) (SEQ ID NO:23, 24, 25) for the antibody, and a suitable J region gene sequence was selected to provide frame region 4 (FR4) (SEQ ID NO:26). This template can be selected based on various factors, including: the relative total length of the antibody, the size of the CDR, the amino acid residues located at the junction between the antibody frame region (FR) and the hypervariable region (CDR), and the overall sequence homology. The selected template can be a mixture of multiple sequences or a shared template, with the aim of maintaining the appropriate conformation of the parental complementarity-determining region (CDR) as much as possible. Simultaneously, considering the solubility, stability, and expression yield of the humanized antibody, four hotspot amino acids 37F / 44E / 45R / 47F in FR2 were reverse-mutated, ultimately yielding the humanized mutant N2G1-h9 (SEQ ID NO:27). Using conventional molecular biology techniques, the nucleotide sequence encoding the variable region of N2G1-h9 (SEQ ID NO:27) was cloned into a eukaryotic expression vector (Invitrogen pcDNA3.1) containing the Fc segment encoding human antibody IgG1 to express the N2G1-h9-Fc recombinant protein.

[0215] 4.2 Affinity analysis of humanized TCRm antibodies against the HLA-A02 / NDC80 complex

[0216] Referring to Example 3.2, the affinity analysis of the recombinant anti-HLA-A02 / NDC80 TCRm antibody N2G1-h9 was performed using a Biacore T200. In addition to the HLA-A0201 / NDC80 complex, the HLA-A02 / NDC80 complex also contained the HLA-A / NDC80 complex containing HLA-A0203 / 0206 / A0207 prepared in Example 1. N2G1-h9 did not bind to the HLA-A0206 / NDC80 complex. The binding fitting results with the MIP-N1-A0201 / A0203 / A0207 complex are shown in Table 2.

[0217] Table 2. Affinity of TCRm antibody N2G1-h9 against HLA-A02 / NDC80 complex to MIP-N1-A0201 / A0203 / A0207

[0218] Example 5: Preparation and identification of TCRm / anti-CD3 bispecific antibody

[0219] 5.1 Preparation of TCRm / anti-CD3 bispecific antibody

[0220] In this embodiment, two TCRm / anti-CD3 bispecific antibodies, N2G1 / anti-CD3 and N2G1-h9 / anti-CD3, were prepared. These two bispecific antibodies are based on N2G1 or N2G1-h9 and a single-chain antibody against CD3E (anti-CD3-ScFv, SEQ ID NO:28, see US Patent 5821337A).

[0021] The nucleotide sequence encoding the N2G1 heavy chain variable region (SEQ ID NO:17) or the N2G1-h9 heavy chain variable region (SEQ ID NO:27) was cloned into a eukaryotic expression vector fused with the nucleotide sequence encoding the Hole mutation Fc fragment IgG1m3-FcH1n1-3C (SEQ ID NO:37). The nucleotide sequence encoding anti-CD3-ScFv (SEQ ID NO:28) was cloned into a eukaryotic expression vector fused with the Knob mutation Fc fragment IgG1m3-FcKn1-3C (SEQ ID NO:38). Additionally, a TCRm / anti-CD3 bispecific antibody isotype control antibody DP47 / anti-CD3 was prepared. The nucleotide sequence of VH (SEQ ID NO:21) encoding DP47 was cloned into a eukaryotic expression vector fused with the nucleotide sequence encoding CH-IgG1m3-H1n1 (SEQ ID NO:13); the nucleotide sequence of VK (SEQ ID NO:22) encoding DP47 was cloned into a eukaryotic expression vector encoding the nucleotide sequence Cκ (SEQ ID NO:16). The constructed eukaryotic expression vectors expressing N2G1-G1m3-FcH1n1-3C (SEQ ID NO:39) or N2G1-h9-G1m3-FcH1n1-3C (SEQ ID NO:40) and anti-CD3-ScFv-G1m3-FcKn1-3C (SEQ ID NO:41), or the constructed eukaryotic expression vectors expressing DP47VH-IgG1m3-H1n1 (SEQ ID NO:87) and DP47VK-Cκ (SEQ ID NO:88) and the eukaryotic expression vector expressing anti-CD3-ScFv-G1m3-FcKn1-3C (SEQ ID NO:41) were co-transfected into HEK293F cells using liposomes. The cells were cultured in serum-free suspension culture for 3-5 days, and then the culture supernatant was harvested by centrifugation. Bispecific antibodies in the culture supernatant were purified using a Protein A affinity chromatography column (GE's Mabselect SURE). The recombinant protein storage buffer was then replaced with PBS (pH 7.0) using a desalting column (GE's Hitrap desaulting). The desalted protein solution was then purified using size exclusion chromatography (SEC) on a Superdex 200 (GE) to obtain the target protein. If necessary, the antibody samples can be filtered for sterilization and then aliquoted and stored at -20°C for later use.

[0221] 5.2 Affinity analysis of TCRm / anti-CD3 bispecific antibody

[0222] Referring to Example 3.2, the affinity analysis of the recombinant TCRm / anti-CD3 bispecific antibody was performed using Biacore T200, and the fitting results are shown in Tables 3 and 4.

[0223] Table 3: Affinity of TCRm / anti-CD3 bispecific antibody to MIP-N1-A0201

[0224] Table 4: Affinity of TCRm×anti-CD3 bispecific antibody to CD3D-CD3E-mFc

[0225] 5.3 The TCRm / anti-CD3 bispecific antibody simultaneously recognizes antigens MIP-N1-A0201 and CD3.

[0226] Coat 96-well ELISA plates with CD3D-CD3E-mFc antigen (3 μg / mL, 100 μL per well) overnight at 4°C. Block with blocking buffer PBS-0.1% Tween 20-3% skim milk at 37°C for 1 hour. Dilute TCRm / anti-CD3 bispecific antibody to 10 μg / mL with PBS, add 100 μL per well to the blocked 96-well ELISA plates, and incubate at 37°C for 1 hour. Wash the ELISA plates with PBS-0.1% Tween 20, add MIP-N1-A0201 antigen (2 μg / mL, 100 μL per well), and incubate at 37°C for 1 hour. Wash the ELISA plates with PBS-0.1% Tween 20, then add HRP-labeled anti-His-tagged mouse monoclonal antibody (Beijing Kangwei Century Biotechnology Co., Ltd., cw0285M), and incubate at 37°C for 1 hour. The ELISA plate was washed with PBS-0.1% Tween 20, and OPD substrate chromogenic solution was added. The chromogenic reaction was terminated with 1M H2SO4 after 5-10 minutes. The optical density was measured at dual wavelengths of 492nm / 630nm using a microplate reader. The ELISA analysis results are shown in Figure 4. The TCRm / anti-CD3 bispecific antibodies N2G1 / anti-CD3 and N2G1-h9 / anti-CD3 can simultaneously recognize CD3 and MIP-N1-A0201.

[0227] 5.4 T2 cells activating Jurkat-Dual cells mediated by TCRm / anti-CD3 bispecific antibody-mediated antigen peptide pulses

[0228] Collect T2 cells in the logarithmic growth phase, centrifuge, and resuspend in growth medium to a concentration of 1×10⁻⁶. 6 / mL, seeded at 1mL per well in a 24-well plate. Peptide NDC80 274-282(ALNEQIARL) was added to a final concentration of 50 μg / mL in a 24-well plate and incubated overnight. After 16 hours, the plate was centrifuged and resuspended in RPMI 1640 medium to a final volume of 4 × 10⁻⁶. 5 50 μL of Jurkat-Dual cells (purchased from Invivogen) were seeded per well at a concentration of 10 mL / mL into cell plates. Jurkat-Dual cells in the logarithmic growth phase were collected, centrifuged, and resuspended in RPMI 1640 medium to a final volume of 4 × 10⁻⁶. 5 Add 50 μL of the above-mentioned E:T ratio to each well of a cell plate seeded with T2 cells to obtain a final E:T ratio of 1:1. Then add the bispecific antibodies N2G1 / anti-CD3 and N2G1-h9 / anti-CD3 (starting concentration 30 nM, serially diluted 4-fold, 10 concentration points, 100 μL per well). The negative control sample is DP47 / anti-CD3, used at the same concentration as the bispecific antibodies. Incubate for 24 h, collect the supernatant, and follow the instructions for QUANTI-Luc. TM Instruction manual (QUANTI-Luc) TM The specific activation of Jurkat-Dual cells by T2 cells mediated by antigen peptide pulses induced by the bispecific antibodies N2G1 / anti-CD3 and N2G1-h9 / anti-CD3 was detected and analyzed using Invivogen (rep-qlc2). The results, shown in Figure 5, indicate that the bispecific antibodies N2G1 / anti-CD3 and N2G1-h9 / anti-CD3 can specifically mediate the activation of Jurkat-Dual cells by T2 cells mediated by antigen peptide pulses, EC50. 50 The values ​​are 0.0261 nM and 0.0391 nM, respectively.

[0229] 5.5 TCRm / anti-CD3 bispecific antibody mediates PBMC-specific killing of target cells

[0230] 5.5.1 Isolation of human peripheral blood mononuclear cells (PBMCs)

[0231] Blood was collected from healthy volunteers (50 mL each), and all volunteers had signed informed consent forms. Volunteer selection criteria were as follows:

[0232] Over 18 years old;

[0233] No HIV or HBV infection;

[0234] Blood routine test results were normal;

[0235] Non-pregnant or breastfeeding women;

[0236] PBMCs were isolated from whole blood of volunteers using Ficoll density gradient centrifugation and cultured in RPMI 1640 medium.

[0237] 5.5.2 TCRm / anti-CD3 bispecific antibody-mediated PBMC killing of HLA-A02 + / NDC80 + cell

[0238] OCI-AML2 (human acute myeloid leukemia cells, purchased from the Cell Resource Center of the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences; OCI-AML2 cells were HLA-A02 positive and NDC80 positive) and 293T (human kidney epithelial cell line, derived from primary human embryonic kidney cells; 293T cells were HLA-A02 positive and NDC80 target antigen peptide presentation negative) were used. Logarithmic growth phase OCI-AML2 and 293T cells were collected, digested, centrifuged, and resuspended in RPMI 1640 medium to a final volume of 4 × 10⁻⁶. 5 50 μL of the bispecific antibody N2G1 / anti-CD3 and N2G1-h9 / anti-CD3 (starting concentration 10 nM, serially diluted 3-fold, 10 concentration points, 100 μL per well) was added to each well. The negative control sample DP47 / anti-CD3 was used at the same concentration as the bispecific antibody. PBMCs (effective cells) were resuspended to 4 × 10⁶ m³ / h⁻¹. 6 Add 50 μL of the above-mentioned cell culture medium to each well, resulting in a final effector-to-target ratio of 10:1. Simultaneously, set up separate target cell controls, separate effector cell controls (PBMCs), and separate culture medium blank controls, and bring the volume of each well to 200 μL with culture medium. After incubation for 24 hours, collect the supernatant and refer to... Non-radioactive cytotoxicity detection reagents ( The Non-Radioactive Cytotoxicity Assay (Promega, G1780) describes the detection and analysis of TCRm / anti-CD3 bispecific antibody-mediated PBMC cell activity against HLA-A02. + / NDC80 + The cells were killed by OCI-AML2. The results, shown in Figure 6, indicate that the bispecific antibodies N2G1 / anti-CD3 and N2G1-h9 / anti-CD3 specifically mediated the killing of HLA-A02 by PBMCs. + / NDC80 + Cellular OCI-AML2 killing, EC 50 The values ​​are 0.04079 nM and 0.04007 nM, respectively.

[0239] Example 6: TCRm / anti-CD3 bispecific antibody recognizes NDC80 274-282 Key amino acid analysis of (ALNEQIARL)

[0240] Chemical synthesis NDC80 274-282 (ALNEQIARL) alanine-scanning peptide (SEQ ID NO:42-50). Referring to Example 5.4, the specific activation of Jurkat-Dual cells by T2 cells pulsed with the alanine-scanning peptide was detected and analyzed. The results are shown in Figure 7. N2G1-h9 / anti-CD3 could not effectively mediate the activation of Jurkat-Dual cells by T2 cells pulsed with the alanine-scanning mutant peptide at positions 2, 3, 5, 6, and 7, i.e., NDC80. 274-282 The amino acids at positions 2, 3, 5, 6, and 7 of (ALNEQIARL) (i.e., “NDC80” in Figure 7) are the key amino acids for N2G1-h9 / anti-CD3 binding.

[0241] Example 7: Interaction analysis between TCRm / anti-CD3 bispecific antibody and similar peptides

[0242] 7.1 Chemical Synthesis of NDC80 in Table 5 274-282 Similar peptides to (ALNEQIARL), wherein NDC80-S1 to NDC80-S7 (SEQ ID NO:52-58) are derived from the searched peptides related to NDC80. 274-282 (ALNEQIARL) contains antigenic peptides with 6 or more identical amino acids at the same position, while NDC80-N2G1-S1 to NDC80-N2G1-S23 (SEQ ID NO:59-81) are antigenic peptides obtained by searching for N2G1 binding key amino acids and possessing N2G1 binding key amino acids or amino acids with similar properties to the binding key position. Referring to Example 5.4, the activation of Jurkat-Dual cells by T2 cells mediated by N2G1-h9 / anti-CD3 with different similar peptide pulses was detected and analyzed. The results are shown in Figures 8A and 8B. N2G1-h9 / anti-CD3 specifically mediated the activation of Jurkat-Dual cells by T2 cells with the following antigenic peptide pulses: antigenic peptide NDC80 274-282(ALNEQIARL), similar peptides NDC80-S7 (from STXB1, SEQ ID NO:82), NDC80-N2G1-S8 (from NES, SEQ ID NO:83), NDC80-N2G1-S10 (from MSH3, SEQ ID NO:84), and NDC80-N2G1-S16 (from DCTN1, SEQ ID NO:85), without mediating the activation of Jurkat-Dual by T2 cells loaded with other similar peptides. Furthermore, T2 cells loaded with similar peptides NDC80-S7, NDC80-N2G1-S8, NDC80-N2G1-S10, and NDC80-N2G1-S16 showed lower activation activity against Jurkat-Dual cells than those loaded with NDC80-S7. 274-282 .

[0243] Table 5. NDC80 274-282 (ALNEQIARL) similar peptide

[0244] 7.2 The genes corresponding to the similar peptides with activating activity in Example 7.1 above, namely STXB1 (sequence shown as SEQ ID NO:82, represented as 293T-STXB1 in Figures 9A and 9B; corresponding to NDC80-S7), NES (sequence shown as SEQ ID NO:83, represented as 293T-Nestin in Figures 9A and 9B; corresponding to NDC80-N2G1-S8), MSH3 (sequence shown as SEQ ID NO:84, represented as 293T-MSH3 in Figures 9A and 9B; corresponding to NDC80-N2G1-S10), DCTN1 (sequence shown as SEQ ID NO:85, represented as 293T-DCTN1 in Figures 9A and 9B; corresponding to NDC80-N2G1-S16), and NDC80 (sequence shown as SEQ ID NO:2, represented as 293T-NDC80 in Figures 9A and 9B; corresponding to NDC80), are also included. 274-282The cells were cloned into transient eukaryotic expression vectors and then transiently transfected into HLA-A02-positive 293T cells that did not present the NDC80 target antigen peptide using liposomes (see Example 1). Referring to Examples 5.4 and 5.5, the activity of the N2G1-h9 / anti-CD3 bispecific antibody in mediated activation of Jurkat-Dual cells by these cells and the killing activity of PBMCs in these cells were analyzed. The results are shown in Figures 9A and 9B. The N2G1-h9 / anti-CD3 bispecific antibody did not mediate the activation of Jurkat-Dual cells by 293T cells transfected with the similar peptide gene (Figure 9A); similarly, the N2G1-h9 / anti-CD3 bispecific antibody did not mediate the killing of 293T cells transfected with the similar peptide gene by PBMCs (Figure 9B).

[0245] Example 8: TCRm / anti-CD3 bispecific antibody inhibits tumor growth in mice

[0246] 8.1 TCRm / anti-CD3 bispecific antibody inhibits the growth of OCI-AML2 tumor cells in a mouse in vivo hematologic malignancy model.

[0247] NOG mice (Beijing Vital River Laboratory Animal Technology Co., Ltd.) (female, 6-8 weeks old) were used as experimental subjects. Human peripheral blood lymphocytes were collected 14 days prior to the experiment according to section 5.5.1, at a concentration of 1×10⁻⁶. 7 / Inoculation was performed only on NOG mice, and 7 days prior to the start of the experiment, OCI-AML2 tumor cell suspension collected and suspended after culture was added at a concentration of 1×10⁻⁶. 7 Mice were subcutaneously injected unilaterally into the abdomen with PBMCs (100 μL injection volume) to establish a mouse model of xenografting of human acute myeloid leukemia tumor cells with PBMC immune reconstitution.

[0248] On the first day of the experiment, the major diameter (a) and minor diameter (b) of the formed tumors in each mouse were measured using vernier calipers, and the tumor volume was calculated using the following formula: V = a × b 2 / 2. Mice were randomly divided into 4 groups according to tumor volume, with 10 mice in each group. The average tumor volume was 200 mm². 3Mice were administered the drugs on the day of grouping. In group 1, mice were given intravenously the control antibody DP47 / anti-CD3 at 0.3 mg / kg, once a week for 3 weeks; in group 2, mice were given intravenously the bispecific antibody N2G1-h9 / anti-CD3 at 0.3 mg / kg, once a week for 3 weeks; in group 3, mice were given intravenously the bispecific antibody N2G1-h9 / anti-CD3 at 0.1 mg / kg, once a week for 3 weeks; and in group 4, mice were given intravenously the bispecific antibody N2G1-h9 / anti-CD3 at 0.01 mg / kg, once a week for 3 weeks.

[0249] From the start of the experiment, the tumor diameter and volume of mice were measured and calculated every 3 days using the method described above, continuing until the mice's movement was affected by the excessive size of the tumor or the tumor regressed. The tumor volume data for each group of mice were statistically analyzed. The experimental results are shown in Figure 10. The N2G1-h9 / anti-CD3 bispecific antibody at a dose of 0.1 mg / kg or higher significantly inhibited the growth of OCI-AML2 tumors in vivo.

[0250] 8.2 TCRm / anti-CD3 bispecific antibody inhibits the growth of HepG2 tumor cells in a mouse solid tumor model.

[0251] A mouse model of HepG2 xenograft of human liver cancer cells (PBMCs) was constructed according to Example 8.1. Mice were randomly divided into four groups of 10 mice each, based on tumor volume. The average tumor volume was 90 mm². 3 Mice were administered the drugs on the day of grouping. In group 1, mice were given intravenously the control antibody DP47 / anti-CD3 at 1.4 mg / kg, once a week for 3 weeks; in group 2, mice were given intravenously the bispecific antibody N2G1-h9 / anti-CD3 at 3 mg / kg, twice a week for 3 weeks; in group 3, mice were given intravenously the bispecific antibody N2G1-h9 / anti-CD3 at 1 mg / kg, twice a week for 3 weeks; and in group 4, mice were given intravenously the bispecific antibody N2G1-h9 / anti-CD3 at 0.3 mg / kg, twice a week for 3 weeks.

[0252] From the start of the experiment, the diameter and volume of mouse tumors were measured every 3 days until the mice became too large to move or the tumors regressed. The tumor volumes of each group of mice were statistically analyzed. The experimental results are shown in Figure 11. The N2G1-h9 / anti-CD3 bispecific antibody at doses of 0.3 mg / kg or higher significantly inhibited the growth of HepG2 tumors in vivo.

[0253] Sequence information

[0254] SEQ ID NO:1(NDC80 274-282 )

[0255] SEQ ID NO:2(NDC80)

[0256] SEQ ID NO:3(hCD3E)

[0257] SEQ ID NO:4(hCD3D)

[0258] SEQ ID NO:5(MIP-N1-A0201)

[0259] SEQ ID NO:6(His)

[0260] SEQ ID NO:7(mFc)

[0261] SEQ ID NO:8(CH-IgG1)

[0262] SEQ ID NO:9(CH-IgG1H)

[0263] SEQ ID NO:10(CH-IgG1K)

[0264] SEQ ID NO:11(CH-IgG1m3-H)

[0265] SEQ ID NO:12(CH-IgG1m3-K)

[0266] SEQ ID NO:13(CH-IgG1m3-H1n1)

[0267] SEQ ID NO:14(CH-IgG1m3-Kn1)

[0268] SEQ ID NO:15(Cλ)

[0269] SEQ ID NO:16(Cκ)

[0270] SEQ ID NO:17(N2G1)

[0271] SEQ ID NO:18(N2G1-HCDR1)

[0272] SEQ ID NO:19(N2G1-HCDR2)

[0273] SEQ ID NO:20(N2G1-HCDR3)

[0274] SEQ ID NO:21(DP47VH)

[0275] SEQ ID NO:22(DP47VK)

[0276] SEQ ID NO:23(N2G1-h9-FR1)

[0277] SEQ ID NO:24(N2G1-h9-FR2)

[0278] SEQ ID NO:25(N2G1-h9-FR3)

[0279] SEQ ID NO:26(N2G1-h9-FR4)

[0280] SEQ ID NO:27(N2G1-h9)

[0281] SEQ ID NO:28(anti-CD3-ScFv)

[0282] SEQ ID NO:29(anti-CD3-VH)

[0283] SEQ ID NO:30(anti-CD3-VH-HCDR1)

[0284] SEQ ID NO:31(anti-CD3-VH-HCDR2)

[0285] SEQ ID NO:32(anti-CD3-VH-HCDR3)

[0286] SEQ ID NO:33(anti-CD3-VK)

[0287] SEQ ID NO:34(anti-CD3-VK-LCDR1)

[0288] SEQ ID NO:35(anti-CD3-VK-LCDR2)

[0289] SEQ ID NO:36(anti-CD3-VK-LCDR3)

[0290] SEQ ID NO:37(IgG1m3-FcH1n1-3C)

[0291] SEQ ID NO:38(IgG1m3-FcKn1-3C)

[0292] SEQ ID NO:39(N2G1-G1m3-FcH1n1-3C)

[0293] SEQ ID NO:40(N2G1-h9-G1m3-FcH1n1-3C)

[0294] SEQ ID NO:41(anti-CD3-ScFv-G1m3-FcKn1-3C)

[0295] SEQ ID NO:42(NDC80-A1G)

[0296] SEQ ID NO:43(NDC80-L2A)

[0297] SEQ ID NO:44(NDC80-N3A)

[0298] SEQ ID NO:45(NDC80-E4A)

[0299] SEQ ID NO:46(NDC80-Q5A)

[0300] SEQ ID NO:47(NDC80-I6A)

[0301] SEQ ID NO:48(NDC80-A7G)

[0302] SEQ ID NO:49(NDC80-R8A)

[0303] SEQ ID NO:50(NDC80-L9A)

[0304] SEQ ID NO:51(unrelated peptide)

[0305] SEQ ID NO:52(NDC80-S1)

[0306] SEQ ID NO:53(NDC80-S2)

[0307] SEQ ID NO:54(NDC80-S3)

[0308] SEQ ID NO:55(NDC80-S4)

[0309] SEQ ID NO:56(NDC80-S5)

[0310] SEQ ID NO:57(NDC80-S6)

[0311] SEQ ID NO:58(NDC80-S7)

[0312] SEQ ID NO:59(NDC80-N2G1-S1)

[0313] SEQ ID NO:60(NDC80-N2G1-S2)

[0314] SEQ ID NO:61(NDC80-N2G1-S3)

[0315] SEQ ID NO:62(NDC80-N2G1-S4)

[0316] SEQ ID NO:63(NDC80-N2G1-S5)

[0317] SEQ ID NO:64(NDC80-N2G1-S6)

[0318] SEQ ID NO:65(NDC80-N2G1-S7)

[0319] SEQ ID NO:66(NDC80-N2G1-S8)

[0320] SEQ ID NO:67(NDC80-N2G1-S9)

[0321] SEQ ID NO:68(NDC80-N2G1-S10)

[0322] SEQ ID NO:69(NDC80-N2G1-S11)

[0323] SEQ ID NO:70(NDC80-N2G1-S12)

[0324] SEQ ID NO:71(NDC80-N2G1-S13)

[0325] SEQ ID NO:72(NDC80-N2G1-S14)

[0326] SEQ ID NO:73(NDC80-N2G1-S15)

[0327] SEQ ID NO:74(NDC80-N2G1-S16)

[0328] SEQ ID NO:75(NDC80-N2G1-S17)

[0329] SEQ ID NO:76(NDC80-N2G1-S18)

[0330] SEQ ID NO:77(NDC80-N2G1-S19)

[0331] SEQ ID NO:78(NDC80-N2G1-S20)

[0332] SEQ ID NO:79(NDC80-N2G1-S21)

[0333] SEQ ID NO:80(NDC80-N2G1-S22)

[0334] SEQ ID NO:81(NDC80-N2G1-S23)

[0335] SEQ ID NO:82(STXB1_HUMAN)

[0336] SEQ ID NO:83(NES_HUMAN)

[0337] SEQ ID NO:84(MSH3_HUMAN)

[0338] SEQ ID NO:85(DCTN1_HUMAN)

[0339] SEQ ID NO:86(Primer PCal-CH2R)

[0340] SEQ ID NO:87(DP47VH-IgG1m3-H1n1)

[0341] SEQ ID NO:88(DP47VK-Cκ)

[0342] SEQ ID NO:89(MIP-N1-A0203)

[0343] SEQ ID NO:90(MIP-N1-A0206)

[0344] SEQ ID NO:91(MIP-N1-A0207)

[0345] References

[0346] 1.Wang JX,Diao TY,Yang XL,Li K,Yang JL,Chen XQ.Implications of the NDC80 complex on the tumor immune microenvironment and cell growth in pan-cancer.J Cancer 2024;15(19):6364-6382.

[0347] 2.Ciferri C,Musacchio A,Petrovic A.The Ndc80 complex:hub of kinetochore activity.FEBS Lett.2007;581:2862-9.

[0348] 3.Sun ZY,Wang W,Gao H,Chen QF.Potential therapeutic targets of the nuclear division cycle 80(NDC80)complexes genes in lung adenocarcinoma.J Cancer.2020;11:2921-34

[0349] 4.Chen Y,Riley DJ,Chen PL,Lee WH.HEC,a novel nuclear protein rich in leucine heptad repeats specifically involved in mitosis.Mol Cell Biol.1997Oct;17(10):6049-56.

[0350] 5.Yu X,Pan M,Jiang L,Liu K.NDC80 Kinetochore Complex Serves as a Potential Prognostic Predictor and Correlates with Immune Infiltrates in Epithelial Ovarian Cancer Patients.Int J Gen Med.2024May2;17:1789-1805.

[0351] 6.Xing XK,Wu HY,Chen HL,Feng HG.NDC80 promotes proliferation and metastasis of colon cancer cells.Genet Mol Res.2016May 6;15(2).

[0352] 7.Yixiang,X.,To′A,S,G.,Ningyan,Z.,et al.,(2019)T-cell receptor mimic(TCRm)antibody therapeutics against intracellular proteins.Antibody Therapeutics 2(1):22-32.

[0353] 8.Horig,H.,Lee,C,S.,Kaufman,H,L.(2002)Prostate-specific antigen vaccines for prostate cancer.Expert Opin Biol Ther2(4):395-408.

[0354] 9.Vlad,A,M.,Kettel,J,C.,Alajez,N,M.,et al.,(2004)MUC1 immunobiology:from discovery to clinical applications.Advances in Immunology 82:249-293.

[0355] 10.Klatt MG,Dao T,Yang Z,Liu J,Mun SS,Dacek MM,Luo H,Gardner TJ,Bourne C,Peraro L,Aretz ZEH,Korontsvit T,Lau M,Kharas MG,Liu C,Scheinberg DA.A TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematologic malignancies.Blood.2022Aug 25;140(8):861-874.

[0356] 11. Kabat. Sequences of Proteins of Immunological Interest. National Institutes of Health, Bethesda, Md. (1991).

[0357] 12. A1-Lazikani et al. J. Mol. Biol. 273:927-948 (1997).

[0358] 13. Martin et al. Proc. Natl. Acad. Sci. USA 86:9268-9272 (1989).

[0359] 14. "An efficient route to human bispecific IgG", A. Margaret Merchant et al., Nature Biotechnology, Volume 16, 1998.

[0360] 15. Kotsiou E, Brzostek J, Lenart I, Antoniou AN, Dyson J, Gould KG. Dimerization of soluble disulfide trap single-chain major histocompatibility complex class I molecules dependent on peptide binding affinity. Antioxid Redox Signal. 2011 Aug 1; 15(3):635-44.

[0361] 16. E, Poignavent V, Vincke C, Ritzenthaler C, Muyldermans S, Monsion B. Construction of High-Quality Camel Immune Antibody Libraries. Methods Mol Biol. 2018; 1701:169-187.

[0362] 17. Chinese Invention Patent Application Publication CN105315371A.

[0363] 18. Phage Display: A Universal Laboratory Guide / Edited by Clackson, T., and Lowman, HB.; Translated by Ma Lan et al. Chemical Industry Press, May 2008.

[0364] 19. US Patent Application US2016 / 0200833 A1.

[0365] 20.Tan,P.,Mitchell,D,A.,Buss,T,N.,et al.(2022)"Superhumanized"antibodies:reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences:application to an anti-CD28.J Immunol 169(2):1119-1125.

[0366] 21. US Patent US5821337A.

[0367] All publications and patent documents referenced in this specification are incorporated herein by reference as if each publication or patent were expressly indicated to be incorporated herein by reference individually. Various changes and equivalent substitutions may be made to the embodiments disclosed in this application without departing from the true spirit and scope of the disclosure. Unless the context otherwise requires, any feature, step, or embodiment of the embodiments disclosed herein may be used in combination with any other feature, step, or embodiment.

Claims

1. A bispecific antibody comprising a first antigen-binding fragment that binds to the HLA-A02 / NDC80 complex and a second antigen-binding fragment that binds to activated T-cell antigens; Preferably, the binding epitope of the first antigen-binding fragment to the HLA-A02 / NDC80 complex includes one or more residues from positions 274-282 of the amino acid sequence shown in SEQ ID NO:2; more preferably, the binding epitope of the first antigen-binding fragment to the HLA-A02 / NDC80 complex includes at least one residue from positions 275, 276, 278, 279, and 280 of the amino acid sequence shown in SEQ ID NO:2; and / or The activated T-cell antigen is a CD3 molecule.

2. The bispecific antibody as described in claim 1, wherein... The first antigen-binding fragment comprises HCDR1 with the amino acid sequence shown in SEQ ID NO:18, HCDR2 with the amino acid sequence shown in SEQ ID NO:19, and HCDR3 with the amino acid sequence shown in SEQ ID NO:20; preferably, the first antigen-binding fragment is in the form of a single-domain antibody; more preferably, the first antigen-binding fragment comprises a monovalent or multivalent single-domain antibody binding the HLA-A02 / NDC80 complex; and / or The second antigen-binding fragment comprises the amino acid sequences HCDR1 (SEQ ID NO:30), HCDR2 (SEQ ID NO:31), HCDR3 (SEQ ID NO:32), LCDR1 (SEQ ID NO:34), LCDR2 (SEQ ID NO:35), and LCDR3 (SEQ ID NO:36); preferably, the second antigen-binding fragment is in the form of a single-chain antibody (scFv) or a Fab fragment; more preferably, the second antigen-binding fragment is in the form of scFv. in, The amino acid sequences of HCDR and LCDR are defined according to the Kabat scheme.

3. The bispecific antibody according to any one of claims 1-2, wherein The first antigen-binding fragment contains a heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:17 or 27; and / or The second antigen-binding fragment comprises a heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:29 and a light chain variable region with an amino acid sequence as shown in SEQ ID NO:33; Preferably, the first antigen-binding fragment comprises a heavy chain variable region as shown in SEQ ID NO:17, and the second antigen-binding fragment comprises a heavy chain variable region as shown in SEQ ID NO:29 and a light chain variable region as shown in SEQ ID NO:33; or The first antigen-binding fragment contains a heavy chain variable region as shown in SEQ ID NO:27, and the second antigen-binding fragment contains a heavy chain variable region as shown in SEQ ID NO:29 and a light chain variable region as shown in SEQ ID NO:

33.

4. The bispecific antibody according to any one of claims 1-3, wherein The first antigen-binding fragment and the second antigen-binding fragment are linked by the Fc fragment of the antibody heavy chain constant region; Preferably, the antibody heavy chain constant region Fc fragment comprises a first Fc fragment and a second Fc fragment, one of the first Fc fragment and the second Fc fragment being linked to the first antigen-binding fragment, and the other of the first Fc fragment and the second Fc fragment being linked to the second antigen-binding fragment; and / or The Fc fragment of the antibody heavy chain constant region is the Fc fragment of the IgG1 subtype.

5. The bispecific antibody as described in claim 4, wherein... One of the first Fc fragment and the second Fc fragment contains amino acid C at position 354 and amino acid W at position 366, and the other of the first Fc fragment and the second Fc fragment contains amino acid C at position 349, amino acid S at position 366, amino acid A at position 368, and amino acid V at position 407; and / or The first Fc fragment and the second Fc fragment contain amino acid F at position 234, amino acid E at position 235, and amino acid S at position 331; and / or in, The amino acid positions in the antibody constant region are determined according to EU numbering.

6. The bispecific antibody according to any one of claims 1-5, comprising a first arm binding to the HLA-A02 / NDC80 complex and a second arm binding to an activated T-cell antigen, wherein... The first arm comprises an amino acid sequence as shown in SEQ ID NO:39 or SEQ ID NO:40; and / or The second arm contains an amino acid sequence as shown in SEQ ID NO:

41.

7. A single-domain antibody that binds to the HLA-A02 / NDC80 complex, which contains The amino acid sequence of HCDR1 is shown in SEQ ID NO:

18. The amino acid sequence is HCDR2 as shown in SEQ ID NO:19, and The amino acid sequence is HCDR3 as shown in SEQ ID NO:20; Preferably, the single-domain antibody comprises a heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:17 or 27; in, The amino acid sequence of HCDR is defined according to the Kabat scheme.

8. A nucleic acid molecule encoding a bispecific antibody as described in any one of claims 1-6 or a single-domain antibody as described in claim 7.

9. A vector comprising the nucleic acid molecule of claim 8.

10. A host cell comprising the nucleic acid molecule of claim 8 and / or the vector of claim 9.

11. A pharmaceutical composition comprising the bispecific antibody of any one of claims 1-6, the single-domain antibody of claim 7, the nucleic acid molecule of claim 8, and a pharmaceutically acceptable excipient, diluent, or carrier.

12. Use of the bispecific antibody of any one of claims 1-6, the single-domain antibody of claim 7, the nucleic acid molecule of claim 8, or the pharmaceutical composition of claim 11 in the preparation of a medicament for the prevention or treatment of HLA-A02 / NDC80 positive tumors; Preferably, the HLA-A02 / NDC80 positive tumors are selected from: acute myeloid leukemia, pancreatic cancer, cervical cancer, ovarian cancer, lung cancer, liver cancer, breast cancer, and colon cancer; More preferably, the HLA-A02 / NDC80 positive tumor is acute myeloid leukemia.

13. The bispecific antibody of any one of claims 1-6, the single-domain antibody of claim 7, the nucleic acid molecule of claim 8, or the pharmaceutical composition of claim 11, for the prevention or treatment of HLA-A02 / NDC80 positive tumors; Preferably, the HLA-A02 / NDC80 positive tumors are selected from: acute myeloid leukemia, pancreatic cancer, cervical cancer, ovarian cancer, lung cancer, liver cancer, breast cancer, and colon cancer; More preferably, the HLA-A02 / NDC80 positive tumor is acute myeloid leukemia.

14. A method for preventing or treating HLA-A02 / NDC80 positive tumors, comprising administering to a subject in need an effective amount of any one of the bispecific antibody of claims 1-6, the single-domain antibody of claim 7, the nucleic acid molecule of claim 8, or the pharmaceutical composition of claim 11; Preferably, the HLA-A02 / NDC80 positive tumors are selected from: acute myeloid leukemia, pancreatic cancer, cervical cancer, ovarian cancer, lung cancer, liver cancer, breast cancer, and colon cancer; More preferably, the HLA-A02 / NDC80 positive tumor is acute myeloid leukemia.